

INFORMAZIONI PERSONALI



Emanuela Esposito

 xxxxxxxxxxxxxxxx
 xxxxxxxxxxxxxxxx 
 eesposito@unime.it

Sesso F | Data di nascita xxxxxxxxxxxxxxxx Nazionalità Italia

ESPERIENZA LAVORATIVA

- **2012-2017**: Ricercatore in Farmacologia (BIO/14), Dipartimento di Scienze Chimiche, Biologiche, Farmaceutiche ed Ambientali, Università di Messina.
- **2017-2019**: Professore Associato in Farmacologia (BIO/14), Dipartimento di Scienze Chimiche, Biologiche, Farmaceutiche ed Ambientali, Università di Messina.
- **2019-presente**: Professore Ordinario in Farmacologia (BIO/14), Dipartimento di Scienze Chimiche, Biologiche, Farmaceutiche ed Ambientali, Università di Messina.
- **2018-presente**: Direttore del Master di II livello in "Tecniche di preparazione dei farmaci antitumorali e valutazione della sicurezza ed efficacia dei dispositivi medici - II Edizione", Università di Messina.
- **2020-presente**: Direttore della Scuola di Specializzazione in Farmacia Ospedaliera, Università di Messina.
- **2020-presente**: Direttore U.O.S.D. Genetica e Farmacogenetica presso l'Azienda Ospedaliera Universitaria "G. Martino".
- **2020-presente**: Vice-Coordiatore del Dottorato di Ricerca in "Biologia Applicata e Medicina Sperimentale Dipartimento di Scienze Chimiche, Biologiche, Farmaceutiche ed Ambientali, Università di Messina.

ESPERIENZA ACCADEMICA

- **1998-2000**: Attività di tirocinio finalizzata alla realizzazione della tesi sperimentale, Dipartimento di Farmacologia Sperimentale, Facoltà di Farmacia, Università di Napoli Federico II, Italia Supervisor: Prof. Di Carlo. "In vitro toxicology, consisting of the development and use of primary cell cultures from animal tissue".
- **2000-2003**: Dottoranda presso il Dipartimento di Farmacologia Sperimentale, Facoltà di Farmacia, Università di Napoli Federico II, Italia. Supervisor: Prof. Di Carlo. "In vitro models of cell culture"
- **2002-2003**: Visiting Scientist presso la Yale University, School of Medicine, Obstetrics Gynecology and Reproductive Sciences.
- **2003-2005**: Borsista presso il Dipartimento di Farmacologia Sperimentale, Facoltà di Farmacia, Università di Napoli Federico II, Italia. Supervisor: Prof. Meli. "Transcriptional mechanisms, target cells and proteins implicated in Glucocorticoid effects".
- **2006**: Visiting Scientist presso l'IRCCS Centro Neurolesi "Bonino-Pulejo", Messina, Italia. "Novel therapeutical pharmacological target for the treatment of chronic inflammatory lung diseases".
- **2006-2007**: Collaboratore Scientifico presso il Centro Regionale di Competenza in Diagnostica e Farmaceutica Molecolari (CRdC DFM).
- **2007-2009**: Borsista presso l'IRCCS Centro Neurolesi "Bonino-Pulejo", Messina, Italia.
- **2010-2012**: Post-Doc in Farmacologia presso il Dipartimento di Medicina Clinica e Sperimentale e Farmacologia, Facoltà di Medicina, Università di Messina. "Identification of pharmacological targets in the autoimmune and inflammatory diseases".

FORMAZIONE

- 2000: Laurea in Farmacia – Università di Napoli Federico II, Italia.
- 2003: Dottorato in Scienze Farmaceutiche, Modulo: Farmacologia, Dipartimento di Farmacologia Sperimentale, Facoltà di Farmacia, Università di Napoli Federico II, Italia.
- 2005: Specializzazione in Farmacologia, Università di Napoli Federico II, Italia.
- 2010: Dottorato in Scienze cliniche e neurobiologiche. Modulo: Farmacologia (XXII ciclo), Dipartimento di Medicina Clinica e Sperimentale e Farmacologia, Facoltà di Medicina, Università di Messina.

Premi:

- 2004: Travel Awards EPHAR 2004, Porto, Portugal, 14-17 Luglio 2004.
- 2008: Vincitore del Premio Farmaindustria 2008 per la ricerca in Farmacologia con l'articolo "Splanchnic ischemia and reperfusion injury is reduced by genetic or pharmacological inhibition of TNF-alpha", Esposito E, Mazzon E, Muià C, Meli R, Sessa E, Cuzzocrea S pubblicato nel Journal of Leukocyte Biology.
- 2009: Travel Awards EUROPEAN SHOCK SOCIETY (ESS) 2009 CONGRESS, Lisbona.
- 2009: Premio Miglior Poster, 34° Congresso Nazionale della Società Italiana di Farmacologia, Rimini, 14-17 Ottobre 2009.
- 2011: Travel Awards XIV Congress of the European Shock Society, Giardini Naxos, 31 Agosto – 2 Settembre 2011
- 2011: Premio Miglior Poster, EUROPEAN SHOCK SOCIETY CONGRESS, Giardini Naxos, 31 Agosto – 2 Settembre 2011
- 2011: Premio Benedicenti, Miglior Esperto Italiano in Farmacologia
- 2013: Young Scientist Travel Award for Experimental Biology 2013, Boston, MA
- 2014: Young Scientist Travel Award for Experimental Biology 2014, San Diego, CA

ABILITÀ PERSONALI

Lingua Madre ITALIANO

Altre lingue

Inglese

COMPRESIONE		PARLATO		SCRITTURA
Ascolto	Lettura	Interazione	Comunicazione	
Eccellente	Eccellente	Eccellente	Eccellente	Eccellente

Abilità comunicative

- Ottime doti comunicative maturate durante la mia esperienza come Professore Universitario

Capacità organizzative/
manageriali

- Leadership (responsabile di un team composto da più di 10 persone)

Competenze professionali

Attività di ricerca nel campo della Neuroinfiammazione con focus sulla Fisiopatologia delle lesioni del midollo spinale; Fisiopatologia di traumi cerebrali; Fisiopatologia della Malattia di Alzheimer e di Parkinson; Fisiopatologia del dolore neuropatico; Studio di meccanismi neuro-oncologici.
In particolare, l'attività di ricerca mira alla comprensione ed all'approfondimento dei meccanismi biologici del sistema nervoso centrale, attraverso indagini cliniche e di laboratorio, consentendo così lo studio di nuove terapie mirate nel campo della neurodegenerazione, dei neurotraumi e della neuro-oncologia.

- Scrittura di articoli per riviste scientifiche peer-reviewed ad alto impact factor
- Sviluppo di nuovi approcci farmacologici

Competenze digitali

AUTOVALUTAZIONE

Elaborazione delle informazioni	Comunicazione	Creazione di contenuti	Sicurezza	Risoluzione dei problemi
Utente esperto	Utente esperto	Utente esperto	Utente esperto	Utente esperto

- Altre competenze
 - Ottima padronanza di software scientifici (LabView), bibliografici (EndNote) e grafici
 - Esperto di Microsoft Windows™ e MacOS X™.
 - Esperto di Microsoft Office™ (Word™, Excel™, Power Point™, Outlook™).
 - Esperto di acquisizione immagini (Adobe Photoshop™).

Patente di guida B

INFORMAZIONI AGGIUNTIVE

- Progetti**
- 2009: PRIN: "Nuovi meccanismi di trasduzione del segnale dei Glucocorticoidi in infiammazione cronica e immunità" 20094CBRCL_003. Coordinatore: RICCARDI Carlo.
 - 2012: FIRB: "AUTOMED: Analisi dei meccanismi molecolari dell'autofagia nel cancro ed in patologie degenerative". Coordinatore: BALLABIO Andrea.
 - 2012: Young Investigator Programme Fondazione Umberto Veronesi: "Targeting peroxisome proliferator activated receptors (PPARs) as a novel approach in the treatment of graft-versus-host disease (GVHD)". Investigatore principale.
 - 2013: Bando Ricerca Finalizzata "PALMITOYLETHANOLAMIDE TO TARGET INFLAMMATION IN NEURODEGENERATIVE DISEASES: A STUDY FOCUSED ON PERIPHERAL IMMUNE CELLS" # CO-2013-02356242.
 - 2014: Young Against Pain (YAP). "Formation of ceramide and development of morphine-induced hyperalgesia and antinociceptive tolerance". Investigatore principale.
 - 2014: Sviluppo Precompetitivo della Ricerca Farmacologica in Italia: "A new therapy for Multi-Drug Resistant Pseudomonas aeruginosa based on a monoclonal antibody: new therapeutic strategy for lung infections?". Investigatore principale.
 - 2014: Research Project POR 1421 #G63F12000260004 "Alimenti Funzionali e Integratori Nutraceutici a base di Lupino bianco e derivati degli agrumi (ALI.FU.I.DEA)".
 - 2014: Research Project POR 1422 #G63F12000340004 "Valorizzazione di biomasse residuali per l'applicazione nel settore farmaceutico e cosmetico".
 - 2015: Research & Mobility "Effects of N-acylethanolamines and Polyphenols Association in the Control of Neuroinflammation after Traumatic Central Nervous System Injuries". Investigatore principale. Importo finanziato: 78 500 €.
 - 2015: PROGRAMMA DI RICERCA SCIENTIFICA DI RILEVANTE INTERESSE NAZIONALE (PRIN 2015): "MECCANISMI DI PATOGENESI NEGLI STADI PRECOCI DELLA MALATTIA DI ALZHEIMER: IDENTIFICAZIONE DI TARGET FARMACOLOGICI E BIOMARKERS" Protocollo: 2015N4FKJ4_004. Responsabile d'Unità, Durata: 36 mesi. Importo finanziato: 378 890 €.
 - 2017: Research&Mobility "Palmitoylethanolamide-oxazoline (PEA-OXA) and Neuroinflammation: a Novel Therapeutic Strategy for neurodegenerative diseases" – Investigatore principale. Importo finanziato: 72 857 €.
 - 2017: PROGRAMMA DI RICERCA SCIENTIFICA DI RILEVANTE INTERESSE NAZIONALE (PRIN 2017): "Identification and validation of Common pathways at the Crossroads of neurodegeneration and Neuroprotection (COCOON)". Responsabile d'Unità, Durata: 36 mesi, Importo finanziato: 873 440 €.
 - 2019: PROTIDOL "Validazione di un prodotto terapeutico innovativo per la gestione del dolore cronico primario limitando l'infiammazione persistente e la neuroinfiammazione associate", Ente finanziatore: regione Sicilia.
 - 2019: Liver Smart Drug (LSD) "Micro e nano sistemi innovativi per la cura efficace del tumore al fegato", Ente finanziatore: Regione Sicilia.
 - 2020: BONE "Sviluppo di micro e nano tecnologie per la predittività, la diagnosi, la terapia e i trattamenti rigenerativi delle alterazioni patologiche dell'osso e osteo-articolari. Ministero dell'Università e della ricerca.
 - 2020: PROGRAMMA DI RICERCA SCIENTIFICA DI RILEVANTE INTERESSE NAZIONALE (PRIN 2020) Responsabile d'Unità, Durata: 36 mesi.
 - 2022: ANTHEM "Advanced Technologies for Human-centered Medicine, Responsabile Scientifico.
 - 2022: PROGRAMMA DI RICERCA SCIENTIFICA DI RILEVANTE INTERESSE NAZIONALE (PRIN 2020) Coordinatore Scientifico, Durata: 24 mesi. Insights into the prognostic value and immunological role of NAEs degradative enzymes in brain tumors

PARAMETRI SCOPUS

Emanuela Esposito è autrice di più di 300 pubblicazioni e 3 capitoli di libro, ha inoltre partecipato a 133 congressi sia nazionali che internazionali.

- Citazioni: 116000 (Scopus)
- H-index: 58 (Scopus)

PUBBLICAZIONI

1. Meli R, Raso GM, Cicala C, **Esposito E**, Fiorino F, Cirino G. Thrombin. PAR-1 activating peptide increase iNOS expression in cytokine-stimulated C6 glioma cells. *J Neurochem*. 2001 Nov;79(3):556-63. (I.F. **5.546**)
2. Ferrante MC, Meli R, Mattace Raso G, **Esposito E**, Severino L, Di Carlo G, Lucisano A. Effect of fumonisin B1 on structure and function of macrophage plasma membrane. *Toxicol Lett*. 2002 Mar 28;129(3):181-7. (I.F. **4.271**)
3. Raso GM, Pacilio M, Di Carlo G, **Esposito E**, Pinto L, Meli R. In-vivo and in-vitro anti-inflammatory effect of Echinacea purpurea and Hypericum perforatum. *J Pharm Pharmacol*. 2002 Oct;54(10):1379-83. (I.F. **4.810**)
4. Mattace Raso G, Pacilio M, **Esposito E**, Coppola A, Di Carlo R, Meli R. Leptin potentiates IFN-gamma-induced expression of nitric oxide synthase and cyclo-oxygenase-2 in murine macrophage J774A.1. *Br J Pharmacol*. 2002 Nov;137(6):799-804. (I.F. **9.473**)
5. Diano S, Leonard JL, Meli R, **Esposito E**, Schiavo L. Hypothalamic type II iodothyronine deiodinase: a light and electron microscopic study. *Brain Res*. 2003 Jun 20;976(1):130-4. (I.F. **3.61**)
6. Meli R, Pacilio M, Raso GM, **Esposito E**, Coppola A, Nasti A, Di Carlo C, Nappi C, Di Carlo R. Estrogen and raloxifene modulate leptin and its receptor in hypothalamus and adipose tissue from ovariectomized rats. *Endocrinology*. 2004 Jul;145(7):3115-21. (I.F. **5.051**)
7. **Esposito E**, Iacono A, Raso GM, Pacilio M, Coppola A, Di Carlo R, Meli R. Raloxifene, a selective estrogen receptor modulator, reduces carrageenan-induced acute inflammation in normal and ovariectomized rats. *Endocrinology*. 2005 Aug;146(8):3301-8. (I.F. **5.051**)
8. Coppola A, Hughes J, **Esposito E**, Schiavo L, Meli R, Diano S. Suppression of hypothalamic deiodinase type II activity blunts TRH mRNA decline during fasting. *FEBS Lett*. 2005 Aug 29;579(21):4654-8. (I.F. **3.864**)
9. Mattace Raso G, **Esposito E**, Iacono A, Pacilio M, Coppola A, Bianco G, Diano S, Di Carlo R, Meli R. Leptin induces nitric oxide synthase type II in C6 glioma cells. Role for nuclear factor-kappaB in hormone effect. *Neurosci Lett*. 2006 Mar 27;396(2):121-6. (I.F. **3.197**)
10. Cuzzocrea S, Genovese T, Mazzon E, Crisafulli C, Di Paola R, Muià C, Collin M, **Esposito E**, Bramanti P, Thiemeermann C. Glycogen synthase kinase-3 beta inhibition reduces secondary damage in experimental spinal cord trauma. *J Pharmacol Exp Ther*. 2006 Jul;318(1):79-89. (I.F. **4.402**)
11. Ferrante MC, Bilancione M, Raso GM, **Esposito E**, Iacono A, Zaccaroni A, Meli R. Expression of COX-2 and hsp72 in peritoneal macrophages after an acute ochratoxin A treatment in mice. *Life Sci*. 2006 Aug 22;79(13):1242-7. (I.F. **6.78**)
12. Genovese T, Mazzon E, Di Paola R, Muià C, Crisafulli C, Malleo G, **Esposito E**, Cuzzocrea S. Role of peroxisome proliferator-activated receptor-alpha in acute pancreatitis induced by cerulein. *Immunology*. 2006 Aug;118(4):559-70. (I.F. **7.215**)
13. Cuzzocrea S, Nocentini G, Di Paola R, Agostini M, Mazzon E, Ronchetti S, Crisafulli C, **Esposito E**, Caputi AP, Riccardi C. Proinflammatory role of glucocorticoid-induced TNF receptor-related gene in acute lung inflammation. *J Immunol*. 2006 Jul 1;177(1):631-41. (I.F. **5.426**)
14. Cuzzocrea S, Mazzon E, Di Paola R, **Esposito E**, Macarthur H, Matuschak GM, Salvemini D. A role for nitric oxide-mediated peroxynitrite formation in a model of endotoxin-induced shock. *J Pharmacol Exp Ther*. 2006 Oct;319(1):73-81. (I.F. **4.402**)
15. Cuzzocrea S, Genovese T, Mazzon E, Crisafulli C, Min W, Di Paola R, Muià C, Li JH, **Esposito E**, Bramanti P, Xu W, Massuda E, Zhang J, Wang ZQ. Poly(ADP-ribose) glycohydrolase activity mediates post-traumatic inflammatory reaction after experimental spinal cord trauma. *J Pharmacol Exp Ther*. 2006 Oct;319(1):127-38. (I.F. **4.402**)
16. Di Paola R, Mazzon E, Muià C, Crisafulli C, Genovese T, Di Bella P, **Esposito E**, Menegazzi M, Meli R, Suzuki H, Cuzzocrea S. Protective effect of Hypericum perforatum in zymosan-induced multiple organ dysfunction syndrome: relationship to its inhibitory effect on nitric oxide production and its peroxynitrite scavenging activity. *Nitric Oxide*. 2007 Feb;16(1):118-30. (I.F. **4.898**)
17. Crisafulli C, Mazzon E, Muià C, Bella P, **Esposito E**, Meli R, Cuzzocrea S. Effects of combination of melatonin and dexamethasone on acute lung injury in a mice model of carrageenan-induced pleurisy. *J Pineal Res*. 2006 Oct;41(3):228-37. (I.F. **13.007**)
18. Mazzon E, Genovese T, Di Paola R, Muià C, Crisafulli C, Malleo G, **Esposito E**, Meli R, Sessa E, Cuzzocrea S. Effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) polymerase, in a mouse model of acute pancreatitis induced by cerulein. *Eur J Pharmacol*. 2006 Nov 7;549(1-3):149-56. (I.F. **5.195**)
19. Di Paola R, Mazzon E, Muià C, Crisafulli C, Genovese T, Di Bella P, **Esposito E**, Menegazzi M, Meli R, Suzuki H, Cuzzocrea S. Green tea

polyphenol extract attenuates zymosan-induced non-septic shock in mice. *Shock*. 2006 Oct;26(4):402-9. (I.F. **3.533**)

20. Mazzon E*, **Esposito E***, Crisafulli C, Riccardi L, Muià C, Di Bella P, Meli R, Cuzzocrea S. Melatonin modulates signal transduction pathways and apoptosis in experimental colitis. *J Pineal Res*. 2006 Nov;41(4):363-73. (I.F. **13.007**) *co-sharing
21. Cuzzocrea S, Crisafulli C, Mazzon E, **Esposito E**, Muià C, Abdelrahman M, Di Paola R, Thiemermann C. Inhibition of glycogen synthase kinase-3beta attenuates the development of carrageenan-induced lung injury in mice. *Br J Pharmacol*. 2006 Nov;149(6):687-702. (I.F. **9.473**)
22. Cuzzocrea S, Bruscoli S, Crisafulli C, Mazzon E, Agostini M, Muià C, **Esposito E**, Di Virgilio R, Meli R, Vegeto E, Maggi A, Riccardi C. Estrogen receptor antagonist fulvestrant (ICI 182,780) inhibits the anti-inflammatory effect of glucocorticoids. *Mol Pharmacol*. 2007 Jan;71(1):132-44. (I.F. **4.436**)
23. Di Paola R**, **Esposito E***, Mazzon E, Genovese T, Muià C, Crisafulli C, Malleo G, Sessa E, Meli R, Cuzzocrea S. Absence of peroxisome proliferator-activated receptors (PPAR)alpha enhanced the multiple organ failure induced by zymosan. *Shock*. 2006 Nov;26(5):477-84. (I.F. **3.533**) *co-sharing
24. Cuzzocrea S, Ronchetti S, Genovese T, Mazzon E, Agostini M, Di Paola R, **Esposito E**, Muià C, Nocentini G, Riccardi C. Genetic and pharmacological inhibition of G1TR-GITRL interaction reduces chronic lung injury induced by bleomycin instillation. *FASEB J*. 2007 Jan;21(1):117-29. (I.F. **5.834**)
25. Cuzzocrea S, Mazzon E, Genovese T, Crisafulli C, Min WK, Di Paola R, Muià C, Li JH, Malleo G, Xu W, Massuda E, **Esposito E**, Zhang J, Wang ZQ. Role of poly(ADP-ribose) glycohydrolase in the development of inflammatory bowel disease in mice. *Free Radic Biol Med*. 2007 Jan 1;42(1):90-105. (I.F. **8.101**)
26. Cuzzocrea S, Di Paola R, Mazzon E, Crisafulli C, Genovese T, Muià C, Abdelrahman M, **Esposito E**, Thiemermann C. Glycogen synthase kinase 3beta inhibition reduces the development of nonseptic shock induced by zymosan in mice. *Shock*. 2007 Jan;27(1):97-107. (I.F. **3.533**)
27. **Esposito E***, Cuzzocrea S, Meli R. Peroxisome proliferator-activated receptors and shock state. *ScientificWorldJournal*. 2006 Dec 28;6:1770-82. (I.F. **1.830**) *corresponding author
28. **Esposito E**, Mazzon E, Muià C, Meli R, Sessa E, Cuzzocrea S. Splanchnic ischemia and reperfusion injury is reduced by genetic or pharmacological inhibition of TNF-alpha. *J Leukoc Biol*. 2007 Apr;81(4):1032-43. (I.F. **6.011**)
29. Genovese T, Mazzon E, **Esposito E**, Muià C, Di Paola R, Crisafulli C, Bramanti P, Cuzzocrea S. N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone reduces severity of experimental spinal cord injury. *Shock*. 2007 Mar;27(3):258-65. (I.F. **3.533**)
30. Cuzzocrea S, Mazzon E, **Esposito E**, Muià C, Abdelrahman M, Di Paola R, Crisafulli C, Bramanti P, Thiemermann C. Glycogen synthase kinase-3beta inhibition attenuates the development of ischaemia/reperfusion injury of the gut. *Intensive Care Med*. 2007 May;33(5):880-93. (I.F. **41.787**)
31. Genovese T, Mazzon E, **Esposito E**, Muià C, Di Paola R, Crisafulli C, Bramanti P, Cuzzocrea S. Inhibition of tyrosine kinase-mediated cellular signalling by Tyrphostins AG126 and AG556 modulates secondary damage in experimental spinal cord trauma. *Neuropharmacology*. 2007 Jun;52(7):1454-71. (I.F. **5.273**)
32. D'Agostino G, La Rana G, Russo R, Sasso O, Iacono A, **Esposito E**, Raso GM, Cuzzocrea S, Lo Verme J, Piomelli D, Meli R, Calignano A. Acute intracerebroventricular administration of palmitoylethanolamide, an endogenous peroxisome proliferator-activated receptor-alpha agonist, modulates carrageenan-induced paw edema in mice. *J Pharmacol Exp Ther*. 2007 Sep;322(3):1137-43. (I.F. **4.402**)
33. Genovese T, Mazzon E, Crisafulli C, Di Paola R, Muià C, **Esposito E**, Bramanti P, Cuzzocrea S. TNF-alpha blockage in a mouse model of SCI: evidence for improved outcome. *Shock*. 2008 Jan;29(1):32-41. (I.F. **3.533**)
34. Genovese T, Mazzon E, Crisafulli C, **Esposito E**, Di Paola R, Muià C, Di Bella P, Bramanti P, Cuzzocrea S. Effects of combination of melatonin and dexamethasone on secondary injury in an experimental mice model of spinal cord trauma. *J Pineal Res*. 2007 Sep;43(2):140-53. (I.F. **13.007**)
35. Genovese T, Mazzon E, **Esposito E**, Muià C, Di Paola R, Bramanti P, Cuzzocrea S. Beneficial effects of FeTSPP, a peroxynitrite decomposition catalyst, in a mouse model of spinal cord injury. *Free Radic Biol Med*. 2007 Sep 1;43(5):763-80. (I.F. **8.101**)

36. Genovese T, Mazzon E, **Esposito E**, Muià C, Di Paola R, Di Bella P, Bramanti P, Cuzzocrea S. Role of endogenous glutathione in the secondary damage in experimental spinal cord injury in mice. *Neurosci Lett*. 2007 Aug 9;423(1):41-6. (I.F. **3.197**)
37. Cuzzocrea S, Genovese T, Mazzon E, **Esposito E**, Di Paola R, Muià C, Crisafulli C, Peli A, Bramanti P, Chaudry IH. Effect of 17beta-estradiol on signal transduction pathways and secondary damage in experimental spinal cord trauma. *Shock*. 2008 Mar; 29(3): 362-71. (I.F. **3.533**)
38. Malleo G, Mazzon E, Genovese T, Paola RD, Muià C, Caminiti R, **Esposito E**, Bella PD, Cuzzocrea S. Etanercept reduces acute tissue injury and mortality associated to zymosan-induced multiple organ dysfunction syndrome. *Shock*. 2008 May; 29(5):560-71. (I.F. **3.533**)
39. Raso GM, Bianco G, Iacono A, **Esposito E**, Autore G, Ferrante MC, Calignano A, Meli R. Maternal adaptations to pregnancy in spontaneously hypertensive rats: leptin and ghrelin evaluation. *J Endocrinol*. 2007 Sep;194(3):611-9. (I.F. **4.669**)
40. Cuzzocrea S, Genovese T, Mazzon E, **Esposito E**, Muià C, Abdelrahman M, Di Paola R, Bramanti P, Thiemermann C. Glycogen synthase kinase-3beta inhibition attenuates the development of bleomycin-induced lung injury. *Int J Immunopathol Pharmacol*. 2007 Jul-Sep;20(3):619-30. (I.F. **3.298**)
41. Genovese T, Mazzon E, Crisafulli C, **Esposito E**, Di Paola R, Muià C, Di Bella P, Meli R, Bramanti P, Cuzzocrea S. Combination of dexamethasone and etanercept reduces secondary damage in experimental spinal cord trauma. *Neuroscience*. 2007 Nov 30;150(1):168-81. (I.F. **3.708**)
42. Muscoli C, Cuzzocrea S, Ndengele MM, Mollace V, Porreca F, Fabrizi F, **Esposito E**, Masini E, Matuschak GM, Salvemini D. Therapeutic manipulation of peroxynitrite attenuates the development of opiate-induced antinociceptive tolerance in mice. *J Clin Invest*. 2007 Nov;117(11):3530-9. (I.F. **19.456**)
43. **Esposito E**, Cuzzocrea S. The role of nitric oxide synthases in lung inflammation. *Curr Opin Investig Drugs*. 2007 Nov;8(11):899-909. (I.F. **6.206**)
44. Cuzzocrea S, Bruscoli S, Mazzon E, Crisafulli C, Donato V, Di Paola R, Velardi E, **Esposito E**, Nocentini G, Riccardi C. Peroxisome proliferator-activated receptor-alpha contributes to the anti-inflammatory activity of glucocorticoids. *Mol Pharmacol*. 2008 Feb;73(2):323-37. (I.F. **4.436**)
45. Cuzzocrea S, Malleo G, Genovese T, Mazzon E, **Esposito E**, Muià C, Abdelrahman M, Di Paola R, Thiemermann C. Effects of glycogen synthase kinase-3beta inhibition on the development of cerulein-induced acute pancreatitis in mice. *Crit Care Med*. 2007 Dec;35(12):2811-21. (I.F. **9.296**)
46. **Esposito E**, Iacono A, Muià C, Crisafulli C, Mattace Raso G, Bramanti P, Meli R, Cuzzocrea S. Signal transduction pathways involved in protective effects of melatonin in C6 glioma cells. *J Pineal Res*. 2008 Jan;44(1):78-87. (I.F. **13.007**)
47. Malleo G, Mazzon E, Genovese T, Di Paola R, Caminiti R, **Esposito E**, Bramanti P, Cuzzocrea S. Absence of endogenous interleukin-10 enhanced organ dysfunction and mortality associated to zymosan-induced multiple organ dysfunction syndrome. *Cytokine*. 2008 Feb;41(2):136-43. (I.F. **3.926**)
48. Genovese T*, **Esposito E***, Mazzon E, Muià C, Di Paola R, Meli R, Bramanti P, Cuzzocrea S. Evidence for the role of mitogen-activated protein kinase signaling pathways in the development of spinal cord injury. *J Pharmacol Exp Ther*. 2008 Apr;325(1):100-14. (I.F. **4.402**) *co-sharing
49. Genovese T, Mazzon E, **Esposito E**, Di Paola R, Caminiti R, Meli R, Bramanti P, Cuzzocrea S. Effect of thalidomide on signal transduction pathways and secondary damage in experimental spinal cord trauma. *Shock*. 2008 Sep; 30(3): 231-240. (I.F. **3.533**)
50. Mariotto S*, **Esposito E***, Di Paola R, Ciampa A, Mazzon E, de Prati AC, Darra E, Vincenzi S, Cucinotta G, Caminiti R, Suzuki H, Cuzzocrea S. Protective effect of Arbutus unedo aqueous extract in carrageenan-induced lung inflammation in mice. *Pharmacol Res*. 2008 Feb;57(2):110-24. (I.F. **10.334**) *co-sharing
51. **Esposito E**, Genovese T, Caminiti R, Bramanti P, Meli R, Cuzzocrea S. Melatonin regulates matrix metalloproteinases after traumatic experimental spinal cord injury. *J Pineal Res*. 2008 Sep;45(2):149-56. (I.F. **13.007**)
52. Nocentini G, Cuzzocrea S, Genovese T, Bianchini R, Mazzon E, Ronchetti S, **Esposito E**, di Paola R, Bramanti P, Riccardi C. G1TR-Fc fusion protein inhibits gitr triggering and protects from the inflammatory response following spinal cord injury. *Mol Pharmacol*. 2008 Jun; 73(6):1610-21. (I.F. **4.436**)
53. Mattace Raso G, Bianco G, **Esposito E**, Iacono A, Meli R, Autore G. Evaluation of Placental Protein Modifications in Normotensive and Spontaneously Hypertensive Rats. *Placenta*. 2008 May; 29(5):429-35. (I.F. **3.287**)

54. Genovese T*, **Esposito E***, Mazzon E, Di Paola R, Meli R, Bramanti P, Piomelli D, Calignano A, Cuzzocrea S. Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury. *J Pharmacol Exp Ther.* 2008 Jul; 326(1):12-23. (I.F. **4.402**) *co-sharing
55. **Esposito E**, Mazzon E, Riccardi L, Meli R, Cuzzocrea S. Matrix metalloproteinase-9 and metalloproteinase-2 activity and expression is reduced by melatonin during experimental colitis. *J Pineal Res.* 2008 Sep;45(2):166-73. (I.F. **13.007**)
56. Ndengele MM, Cuzzocrea S, **Esposito E**, Mazzon E, Di Paola R, Matuschak GM, Salvemini D. Cyclooxygenases 1 and 2 contribute to peroxynitrite-mediated inflammatory pain hypersensitivity. *FASEB J.* 2008 Sep;22(9):3154-64. (I.F. **5.834**)
57. Mazzon E*, **Esposito E***, Di Paola R, Muià C, Crisafulli C, Genovese T, Caminiti R, Meli R, Bramanti P, Cuzzocrea S. Effect of tumour necrosis factor-alpha receptor 1 genetic deletion on carrageenan-induced acute inflammation: a comparison with etanercept. *Clin Exp Immunol.* 2008 Jul;153(1):136-49. (I.F. **5.732**)
58. Cuzzocrea S, Di Paola R, Genovese T, Mazzon E, **Esposito E**, Crisafulli C, Bramanti P, Salvemini D. Anti-inflammatory and anti-apoptotic effects of Fumonisin B1, an inhibitor of ceramide synthase, in a rodent model of splanchnic ischemia and reperfusion injury. *J Pharmacol Exp Ther.* 2008 Oct;327(1):45-57. (I.F. **4.402**)
59. Genovese T*, **Esposito E***, Mazzon E, Di Paola R, Muià C, Meli R, Bramanti P, Cuzzocrea S. Effect of cyclopentanone prostaglandin 15-deoxy-Delta12, 14PGJ2 on early functional recovery from experimental spinal cord injury. *Shock.* 2008 Aug;30(2):142-152. (I.F. **3.533**) *co-sharing
60. Ferrante MC, Raso GM, Bilancione M, **Esposito E**, Iacono A, Meli R. Differential modification of inflammatory enzymes in J774A.1 macrophages by ochratoxin A alone or in combination with lipopolysaccharide. *Toxicol Lett.* 2008 Sep;181(1):40-6. (I.F. **4.271**)
61. Cuzzocrea S, Genovese T, Mazzon E, **Esposito E**, Crisafulli C, Di Paola R, Bramanti P, Salvemini D. Fumonisin b1 reduces the development of multiple organ failure induced by zymosan in mice. *Shock.* 2009 Feb;31(2):170-7. (I.F. **3.533**)
62. Riccardi L, Mazzon E, Bruscoli S, **Esposito E**, Crisafulli C, Di Paola R, Caminiti R, Riccardi C, Cuzzocrea S. Peroxisome proliferator-activated receptor-alpha modulates the anti-inflammatory effect of glucocorticoids in a model of inflammatory bowel disease in mice. *Shock.* 2009 Mar;31(3):308-16. (I.F. **3.533**)
63. Cuzzocrea S, Deigner HP, Genovese T, Mazzon E, **Esposito E**, Crisafulli C, Di Paola R, Bramanti P, Matuschak G, Salvemini D. Inhibition of ceramide biosynthesis ameliorates pathological consequences of spinal cord injury. *Shock.* 2009 Jun;31(6):634-44. (I.F. **3.533**)
64. Genovese T*, **Esposito E***, Mazzon E, Di Paola R, Meli R, Caminiti R, Bramanti P, Fink MP, Cuzzocrea S. Beneficial effects of ethyl pyruvate in a mouse model of Spinal cord injury. *Shock.* 2009 Aug;32(2):217-27. (I.F. **3.533**) *co-sharing
65. Cannarile L, Cuzzocrea S, Santucci L, Agostini M, Mazzon E, **Esposito E**, Muià C, Coppo M, Di Paola R, Riccardi C. Glucocorticoid-induced leucine zipper is protective in Th1-mediated models of colitis. *Gastroenterology.* 2009 Feb;136(2):530-41. (I.F. **33.883**)
66. Ndengele MN, Cuzzocrea S, Masini E, Vinci MC, **Esposito E**, Muscoli C, Petrusca DN, Mollace V, Mazzon E, Li D, Petrache I, Matuschak GM, Salvemini D. Spinal Ceramide Modulates the Development of Morphine Antinociceptive Tolerance via Peroxynitrite Mediated Nitroxidative Stress and Neuroimmune Activation. *J Pharmacol Exp Ther.* 2009 Apr;329(1):64-75. (I.F. **4.402**)
67. Di Paola R, Mazzon E, Genovese T, Crisafulli C, Bramanti P, Caminiti R, **Esposito E**, Fink MP, Cuzzocrea S. Ethyl pyruvate reduces the development of zymosan-induced generalized inflammation in mice. *Crit Care Med.* 2009 Jan;37(1):270-82. (I.F. **9.296**)
68. Di Paola R*, **Esposito E***, Mazzon E, Riccardi L, Caminiti R, Dal Toso R, Pressi G, Cuzzocrea S. Teupolioside, a phenylpropanoid glycosides of *Ajuga reptans*, biotechnologically produced by IRBN22 plant cell line, exerts beneficial effects on a rodent model of colitis. *Biochem Pharmacol.* 2009 Mar 1;77(5):845-57. (I.F. **6.1**)
69. **Esposito E**, Genovese T, Caminiti R, Bramanti P, Meli R, Cuzzocrea S. Melatonin reduces stress-activated/mitogen-activated protein kinases in spinal cord injury. *J Pineal Res.* 2009 Jan;46(1):79-86. (I.F. **13.007**)
70. Raso GM, **Esposito E**, Iacono A, Pacilio M, Cuzzocrea S, Canani RB, Calignano A, Meli R. Comparative therapeutic effects of metformin and vitamin E in a model of non-alcoholic steatohepatitis in the young rat. *Eur J Pharmacol.* 2009 Feb 14;604(1-3):125-31. (I.F. **5.195**)
71. Genovese T, **Esposito E**, Mazzon E, Di Paola R, Caminiti R, Bramanti P, Cappelani A, Cuzzocrea S. Absence of endogenous interleukin-10 enhances secondary inflammatory process after spinal cord compression injury in mice. *J Neurochem.* 2009 Mar;108(6):1360-72. (I.F. **5.546**)

72. Mazzon E*, **Esposito E***, Di Paola R, Riccardi L, Caminiti R, Dal Toso R, Pressi G, Cuzzocrea S. Effects of verbascoside biotechnologically produced by *Syringa vulgaris* plant cell cultures in a rodent model of colitis. *Naunyn Schmiedebergs Arch Pharmacol*. 2009 Jul;380(1):79-94. (I.F. **3.195**)
73. **Esposito E**, Cuzzocrea S. Superoxide, no, peroxynitrite and PARP in circulatory shock and inflammation. *Front Biosci*. 2009 Jan 1;14:263-96. (I.F. **3.115**)
74. Genovese T, Melani A, **Esposito E**, Mazzon E, Di Paola R, Bramanti P, Pedata F, Cuzzocrea S. THE SELECTIVE ADENOSINE A2A RECEPTOR AGONIST CGS 21680 REDUCES JNK MAPK ACTIVATION IN OLIGODENDROCYTES IN INJURED SPINAL CORD. *Shock*. 2009 Dec;32(6):578-85. (I.F. **3.533**)
75. **Esposito E**, Iacono A, Bianco G, Autore G, Cuzzocrea S, Vajro P, Canani RB, Calignano A, Raso GM, Meli R. Probiotics Reduce the Inflammatory Response Induced by a High-Fat Diet in the Liver of Young Rats. *J Nutr*. 2009 May;139(5):905-11. (I.F. **4.687**)
76. Iacono A, Bianco G, Mattace Raso G, **Esposito E**, d'Emmanuele di Villa Bianca R, Sorrentino R, Cuzzocrea S, Calignano A, Autore G, Meli R. Maternal Adaptation in Pregnant Hypertensive Rats: Improvement of Vascular and Inflammatory Variables and Oxidative Damage in the Kidney. *Am J Hypertens*. 2009 Jul;22(7):777-83. (I.F. **3.080**)
77. D'Agostino G, La Rana G, Russo R, Sasso O, Iacono A, **Esposito E**, Mattace Raso G, Cuzzocrea S, Loverme J, Piomelli D, Meli R, Calignano A. Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-kB nuclear signalling in dorsal root ganglia. *Eur J Pharmacol*. 2009 Jun 24;613(1-3):54-9. (I.F. **5.195**)
78. Genovese T*, **Esposito E***, Mazzon E, Crisafulli C, Paterniti I, Di Paola R, Galuppo M, Bramanti P, Cuzzocrea S. PPAR- α modulate the anti-inflammatory effect of glucocorticoids in the secondary damage in experimental spinal cord trauma. *Pharmacol Res*. 2009 May;59(5):338-50. (I.F. **10.334**) *co-sharing
79. Genovese T, Mazzon E, **Esposito E**, Di Paola R, Murthy K, Neville L, Bramanti P, Cuzzocrea S. Effects of a metalloporphyrinic peroxynitrite decomposition catalyst, ww-85, in a mouse model of spinal cord injury. *Free Radic Res*. 2009 Jul;43(7):631-45. (I.F. **4.288**)
80. Mattace Raso G, Irace C, **Esposito E**, Maffettone C, Di Pascale AI, Santamaria R, Colonna A, Meli R. Ovariectomy and estrogen treatment modulate iron metabolism in rat adipose tissue. *Biochem Pharmacol*. 2009 Oct 15;78(8):1001-7. (I.F. **6.1**)
81. **Esposito E**, Cuzzocrea S. Role of nitroso radicals as drug targets in circulatory shock. *Br J Pharmacol*. 2009 Jun;157(4):494-508. (I.F. **9.473**)
82. Bryant L, Doyle T, Chen Z, Cuzzocrea S, Masini E, Vinci MC, **Esposito E**, Mazzon E, Petrusca DN, Petrache I, Salvemini D. Spinal ceramide and neuronal apoptosis in morphine antinociceptive tolerance. *Neurosci Lett*. 2009 Sep 29;463(1):49-53. (I.F. **3.197**)
83. **Esposito E**, Cuzzocrea S. TNF-alpha as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma. *Curr Med Chem*. 2009;16(24):3152-67. (I.F. **4.740**)
84. Crisafulli C, Bruscoli S, **Esposito E**, Mazzon E, Di Paola R, Genovese T, Bramanti P, Migliorati G, Cuzzocrea S. PPAR-alpha contributes to the anti-inflammatory activity of 17beta-estradiol. *J Pharmacol Exp Ther*. 2009 Dec;331(3):796-807. (I.F. **4.402**)
85. Di Paola R, **Esposito E**, Mazzon E, Caminiti R, Dal Toso R, Pressi G, Cuzzocrea S. 3,5-Dicaffeoyl-4-malonylquinic acid reduced oxidative stress and inflammation in a experimental model of inflammatory bowel disease. *Free Radic Res*. 2010;44(1):74-89. (I.F. **4.288**)
86. **Esposito E**, Dal Toso R, Pressi G, Bramanti P, Meli R, Cuzzocrea S. Protective effect of verbascoside in activated C6 glioma cells: possible molecular mechanisms. *Naunyn Schmiedebergs Arch Pharmacol*. 2010 Jan;381(1):93-105. (I.F. **3.195**)
87. Di Paola R, Melani A, **Esposito E**, Mazzon E, Paterniti I, Bramanti P, Pedata F, Cuzzocrea S. Adenosine A2A receptor-selective stimulation reduces signaling pathways involved in the development of intestine ischemia and reperfusion injury. *Shock*. 2010 May;33(5):541-51. (I.F. **3.533**)
88. Paterniti I, **Esposito E**, Mazzon E, Galuppo M, Di Paola R, Bramanti P, Kapoor A, Thiemermann C, Cuzzocrea S. Evidence for the role of peroxisome proliferator-activated receptor-beta/delta in the development of spinal cord injury. *J Pharmacol Exp Ther*. 2010 May;333(2):465-77. (I.F. **4.402**)
89. Genovese T, Melani A, **Esposito E**, Paterniti I, Mazzon E, Di Paola R, Bramanti P, Linden J, Pedata F, Cuzzocrea S. Selective adenosine A(2a) receptor agonists reduce the apoptosis in an experimental model of spinal cord trauma. *J Biol Regul Homeost Agents* 2010 Jan-Mar;24(1):73-86. (I.F. **2.843**)

90. Di Paola R, Crisafulli C, Mazzon E, **Esposito E**, Paterniti I, Galuppo M, Genovese T, Thiernemann C, Cuzzocrea S. GW0742, a high-affinity PPAR-beta/delta agonist, inhibits acute lung injury in mice. *Shock*. 2010 Apr;33(4):426-35. (I.F. **3.533**)
91. Di Paola R*, **Esposito E***, Mazzon E, Paterniti I, Galuppo M, Cuzzocrea S. GW0742, a selective PPAR-beta/delta agonist, contributes to the resolution of inflammation after gut ischemia/reperfusion injury. *J Leukoc Biol*. 2010 Aug;88(2):291-301. (I.F. **6.011**) *co-sharing
92. **Esposito E**, Cuzzocrea S. New therapeutic strategy for Parkinson's and Alzheimer's disease. *Curr Med Chem*. 2010;17(25):2764-74. (I.F. **4.740**)
93. Doyle T, Bryant L, Muscoli C, Cuzzocrea S, **Esposito E**, Chen Z, Salvemini D. Spinal NADPH oxidase is a source of superoxide in the development of morphine-induced hyperalgesia and antinociceptive tolerance. *Neurosci Lett*. 2010 Oct 11;483(2):85-9. (I.F. **3.197**)
94. **Esposito E**, Paterniti I, Mazzon E, Bramanti P, Cuzzocrea S. Melatonin reduces hyperalgesia associated with inflammation. *J Pineal Res*. 2010 Nov;49(4):321-31. (I.F. **13.007**)
95. **Esposito E**, Mazzon E, Paterniti I, Dal Toso R, Pressi G, Caminiti R, Cuzzocrea S. PPAR-alpha Contributes to the Anti-Inflammatory Activity of Verbascoside in a Model of Inflammatory Bowel Disease in Mice. *PPAR Res*. 2010;2010:917312. (I.F. **4.385**)
96. Genovese T, Paterniti I, Mazzon E, **Esposito E**, Di Paola R, Galuppo M, Bramanti P, Cuzzocrea S. Efficacy of treatment with verbascoside, biotechnologically produced by *Syringa vulgaris* plant cell cultures in an experimental mice model of spinal cord trauma. *Naunyn Schmiedeberg Arch Pharmacol*. 2010 Oct;382(4):331-45. (I.F. **3.195**)
97. Paterniti I, Galuppo M, Mazzon E, Impellizzeri D, **Esposito E**, Bramanti P, Cuzzocrea S. Protective effects of apocynin, an inhibitor of NADPH oxidase activity, in splanchic artery occlusion and reperfusion. *J Leukoc Biol*. 2010 Nov;88(5):993-1003. (I.F. **6.011**)
98. **Esposito E**, Mazzon E, Paterniti I, Impellizzeri D, Bramanti P, Cuzzocrea S. Olprinone attenuates the acute inflammatory response and apoptosis after spinal cord trauma in mice. *PLoS One*. 2010 Sep 7;5(9):e12170. (I.F. **3.58**)
99. Impellizzeri D, Mazzon E, **Esposito E**, Paterniti I, Bramanti P, Cuzzocrea S. Effect of Apocynin, an inhibitor of NADPH oxidase, in the inflammatory process induced by an experimental model of spinal cord injury. *Free Radic Res*. 2011 Feb;45(2):221-36. (I.F. **4.288**)
100. Galuppo M, Nocentini G, Mazzon E, Ronchetti S, **Esposito E**, Riccardi L, Sportoletti P, Di Paola R, Bruscoli S, Riccardi C, Cuzzocrea S. The glucocorticoid-induced TNF receptor family-related protein (GITR) is critical to the development of acute pancreatitis in mice. *Br J Pharmacol*. 2011 Mar;162(5):1186-1201. (I.F. **9.47**)
101. Genovese T, Mazzon E, Paterniti I, **Esposito E**, Bramanti P, Cuzzocrea S. Modulation of NADPH oxidase activation in cerebral ischemia/reperfusion injury in rats. *Brain Res*. 2011 Feb 4;1372:92-102. (I.F. **3.61**)
102. Impellizzeri D*, **Esposito E***, Mazzon E, Paterniti I, Di Paola R, Bramanti P, Cuzzocrea S. Effect of apocynin, a NADPH oxidase inhibitor, on acute lung inflammation. *Biochem Pharmacol*. 2011 Mar;81(5):636-648. (I.F. **6.1**) *co-sharing
103. **Esposito E**, Cuzzocrea S. Anti-TNF therapy in the injured spinal cord. *Trends Pharmacol Sci*. 2011 Feb;32(2):107-15. (I.F. **17.638**)
104. Mazzon E*, **Esposito E***, Di Paola R, Impellizzeri D, Bramanti P, Cuzzocrea S. Olprinone, a specific phosphodiesterase (PDE)-III inhibitor, reduces the development of multiple organ dysfunction syndrome in mice. *Pharmacol Res*. 2011 Jul;64(1):68-79. (I.F. **10.334**) *co-sharing
105. Galuppo M, Di Paola R, Mazzon E, **Esposito E**, Paterniti I, Kapoor A, Thiernemann C, Cuzzocrea S. GW0742, a high affinity PPAR-beta/delta agonist reduces lung inflammation induced by bleomycin instillation in mice. *Int J Immunopathol Pharmacol*. 2010 Oct-Dec;23(4):1033-46. (I.F. **3.298**)
106. Di Paola R, Mazzon E, Galuppo M, **Esposito E**, Bramanti P, Fink MP, Cuzzocrea S. Ethyl pyruvate therapy attenuates experimental severe arthritis caused by type II collagen (CII) in the mouse (CIA). *Int J Immunopathol Pharmacol*. 2010 Oct-Dec;23(4):1087-98. (I.F. **3.298**)
107. Ferrante MC, Mattace Raso G, **Esposito E**, Bianco G, Iacono A, Clausi MT, Amero P, Santoro A, Simeoli R, Autore G, Meli R. Effects of non-dioxin-like polychlorinated biphenyl congeners (PCB 101, PCB 153 and PCB 180) alone or mixed on J774A.1 macrophage cell line: modification of apoptotic pathway. *Toxicol Lett*. 2011 Apr 10;202(1):61-8. (I.F. **4.271**)
108. Paterniti I, Mazzon E, Gil C, Impellizzeri D, Palomo V, Redondo M, Perez DI, **Esposito E**, Martinez A, Cuzzocrea S. PDE 7 Inhibitors: New Potential Drugs for the Therapy of Spinal Cord Injury. *PLoS One*. 2011 Jan 31;6(1):e15937. (I.F. **3.58**)

109. Rinaldi B, Donniacuo M, **Esposito E**, Capuano A, Sodano L, Mazzon E, Di Paola R, Paterniti I, Cuzzocrea S, Rossi F. PPAR α mediates the anti-inflammatory effect of simvastatin in an experimental model of zymosan-induced multiple organ failure. *Br J Pharmacol*. 2011 Jun;163(3):609-23. (I.F. **9,47**)
110. **Esposito E**, Paterniti I, Mazzon E, Genovese T, Di Paola R, Galuppo M, Cuzzocrea S. Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury. *Brain Behav Immun*. 2011 Aug;25(6):1099-112. (I.F. **19,227**)
111. **Esposito E**, Cuzzocrea S. Antiinflammatory activity of melatonin in central nervous system. *Curr Neuropharmacol*. 2010 Sep;8(3):228-42. (I.F. **7,708**)
112. **Esposito E**, Mondello S, Di Paola R, Mazzon E, Italiano D, Paterniti I, Mondello P, Aloisi C, Cuzzocrea S. Glutamine contributes to ameliorate inflammation after renal ischemia/reperfusion injury in rats. *Naunyn Schmiedebergs Arch Pharmacol*. 2011 May;383(5):493-508. (I.F. **3,195**)
113. Impellizzeri D*, **Esposito E***, Mazzon E, Paterniti I, Di Paola R, Bramanti P, Morittu VM, Procopio A, Britti D, Cuzzocrea S. The effects of oleuropein aglycone, an olive oil compound, in a mouse model of carrageenan-induced pleurisy. *Clin Nutr*. 2011 Aug;30(4):533-40. (I.F. **7,643**)
***co-sharing**
114. De Santi L, Polimeni G, Cuzzocrea S, **Esposito E**, Sessa E, Annunziata P, Bramanti P. Neuroinflammation and neuroprotection: an update on (future) neurotrophin-related strategies in multiple sclerosis treatment. *Curr Med Chem*. 2011;18(12):1775-84. (I.F. **4,74**)
115. Paterniti I, Melani A, Cipriani S, Corti F, Mello T, Mazzon E, **Esposito E**, Bramanti P, Cuzzocrea S, Pedata F. Selective adenosine A2A receptor agonists and antagonists protect against spinal cord injury through peripheral and central effects. *J Neuroinflammation*. 2011 Apr 12;8(1):31. (I.F. **9,587**)
116. **Esposito E**, Paterniti I, Mazzon E, Genovese T, Galuppo M, Meli R, Bramanti P, Cuzzocrea S. MK801 attenuates secondary injury in a mouse experimental compression model of spinal cord trauma. *BMC Neurosci*. 2011 Apr 14;12(1):31. (I.F. **3,264**)
117. Paterniti I*, **Esposito E***, Mazzon E, Bramanti P, Cuzzocrea S. Evidence for the role of PI(3) -kinase-AKT-eNOS signalling pathway in secondary inflammatory process after spinal cord compression injury in mice. *Eur J Neurosci*. 2011 Apr;33(8):1411-20. (I.F. **4,68**) ***co-sharing**
118. Galuppo M*, **Esposito E***, Mazzon E, Di Paola R, Paterniti I, Impellizzeri D, Cuzzocrea S. MEK inhibition suppresses the development of lung fibrosis in the bleomycin model. *Naunyn Schmiedebergs Arch Pharmacol*. 2011 Jul;384(1):21-37. (I.F. **3,195**) ***co-sharing**
119. Raso GM*, **Esposito E***, Vitiello S, Iacono A, Santoro A, D'Agostino G, Sasso O, Russo R, Piazza PV, Calignano A, Meli R. Palmitoylethanolamide stimulation induces allopregnanolone synthesis in C6 Cells and primary astrocytes: involvement of peroxisome-proliferator activated receptor- α . *J Neuroendocrinol*. 2011 Jul;23(7):591-600. (I.F. **3,870**) ***co-sharing**
120. Galuppo M, Nocentini G, Mazzon E, Ronchetti S, **Esposito E**, Riccardi L, Di Paola R, Bruscoli S, Riccardi C, Cuzzocrea S. G1TR Gene Deletion and G1TR-FcSoluble Protein Administration Inhibit Multiple Organ Failure Induced by Zymosan. *Shock*. 2011 Sep;36(3):263-71. (I.F. **3,533**)
121. **Esposito E**, Paterniti I, Meli R, Bramanti P, Cuzzocrea S. GW0742, A High Affinity PPAR- δ agonist, Mediates Protection in an Organotypic Model of Spinal Cord Damage. *Spine (Phila Pa 1976)*. 2012 Jan 15;37(2):E73-8. (I.F. **3,241**)
122. **Esposito E**, Cuzzocrea S. Targeting the peroxisome proliferator-activated receptors (PPARs) in spinal cord injury. *Expert Opin Ther Targets*. 2011 Aug;15(8):943-59. (I.F. **6,902**)
123. Impellizzeri D, Di Paola R, **Esposito E**, Mazzon E, Paterniti I, Melani A, Bramanti P, Pedata F, Cuzzocrea S. CGS 21680, an agonist of the adenosine (A2A) receptor, decreases acute lung inflammation. *Eur J Pharmacol*. 2011 Oct 1;668(1-2):305-16. (I.F. **5,195**)
124. Mazzon E*, **Esposito E***, Impellizzeri D, Di Paola R, Melani A, Bramanti P, Pedata F, Cuzzocrea S. CGS 21680, an Agonist of the Adenosine (A2A) Receptor, Reduces Progression of Murine Type II Collagen-induced Arthritis. *J Rheumatol*. 2011 Oct;38(10):2119-29. (I.F. **5,346**) ***co-sharing**
125. Genovese T, Mazzon E, Paterniti I, **Esposito E**, Cuzzocrea S. Neuroprotective effects of olprinone after cerebral ischemia/reperfusion injury in rats. *Neurosci Lett*. 2011 Oct 3;503(2):93-9. (I.F. **3,197**)
126. Impellizzeri D*, **Esposito E***, Mazzon E, Paterniti I, Di Paola R, Morittu VM, Procopio A, Britti D, Cuzzocrea S. Oleuropein aglycone, an

- olive oil compound, ameliorates development of arthritis caused by injection of collagen type II in the mice. *J Pharmacol Exp Ther.* 2011 Dec;339(3):859-69. (I.F. **4.402**) *co-sharing
127. Ahmad A, Mondello S, Di Paola R, Mazzone E, **Esposito E**, Catania MA, Italiano D, Mondello P, Aloisi C, Cuzzocrea S. Protective effect of apocynin, a NADPH-oxidase inhibitor, against contrast-induced nephropathy in the diabetic rats: A comparison with n-acetylcysteine. *Eur J Pharmacol.* 2012 Jan 15;674(2-3):397-406. (I.F. **5.195**)
128. **Esposito E**, Bruscoli S, Mazzone E, Paterniti I, Coppo M, Velardi E, Cuzzocrea S, Riccardi C. Glucocorticoid-Induced Leucine Zipper (GILZ) Over-Expression in T Lymphocytes Inhibits Inflammation and Tissue Damage in Spinal Cord Injury. *Neurotherapeutics.* 2012 Jan;9(1):210-25. (I.F. 6.088)
129. Mazzone E, Impellizzeri D, Di Paola R, Paterniti I, **Esposito E**, Cappellani A, Bramanti P, Cuzzocrea S. Effects of Mitogen-Activated Protein Kinase Signaling Pathway Inhibition on the Development of Cerulein-Induced Acute Pancreatitis in Mice. *Pancreas.* 2012 May;41(4):560-70. (I.F. **3.243**)
130. Impellizzeri D, **Esposito E**, Mazzone E, Paterniti I, Di Paola R, Bramanti P, Morittu VM, Procopio A, Perri E, Britti D, Cuzzocrea S. The effects of a polyphenol present in olive oil, oleuropein aglycone, in an experimental model of spinal cord injury in mice. *Biochem Pharmacol.* 2012 May 15;83(10):1413-26. (I.F. **6.1**)
131. Paterniti I, Mazzone E, Riccardi L, Galuppo M, Impellizzeri D, **Esposito E**, Cappellani A, Bramanti P, Cuzzocrea S. Peroxisome proliferator-activated receptor β/δ agonist GW0742 ameliorates cerulein- and taurocholate-induced acute pancreatitis in mice. *Surgery* 2012 Jul;152(1):90-106. (I.F. **4.348**)
132. Di Paola R, Impellizzeri D, Torre A, Mazzone E, Cappellani A, Faggio C, **Esposito E**, Trischitta F, Cuzzocrea S. Effects of palmitoylethanolamide on intestinal injury and inflammation caused by ischemia-reperfusion in mice. *J Leukoc Biol.* 2012 Jun;91(6):911-20. (I.F. **6.011**)
133. **Esposito E**, Impellizzeri D, Mazzone E, Fakhfour G, Rahimian R, Travelli C, Tron GC, Genazzani AA, Cuzzocrea S. The NAMPT inhibitor FK866 reverts the damage in spinal cord injury. *J Neuroinflammation* 2012 Apr 10;9:66. (I.F. **9.587**)
134. **Esposito E**, Rinaldi B, Mazzone E, Donniacuo M, Impellizzeri D, Paterniti I, Capuano A, Bramanti P, Cuzzocrea S. Anti-inflammatory effect of simvastatin in an experimental model of spinal cord trauma: involvement of PPAR- α . *J Neuroinflammation.* 2012 Apr 26;9:81. (I.F. **9.587**)
135. Doyle T, Chen Z, Muscoli C, Bryant L, **Esposito E**, Cuzzocrea S, Dagostino C, Ryerse J, Rausaria S, Kamadulski A, Neumann WL, Salvemini D. Targeting the overproduction of peroxynitrite for the prevention and reversal of paclitaxel-induced neuropathic pain. *J Neurosci.* 2012 May 2;32(18):6149-60. (I.F. **6.709**)
136. Talero E, Di Paola R, Mazzone E, **Esposito E**, Motilva V, Cuzzocrea S. Anti-inflammatory effects of adrenomedullin on acute lung injury induced by Carrageenan in mice. *Mediators Inflamm.* 2012;2012:717851. (I.F.4.529)
137. **Esposito E**, Cuzzocrea S. Palmitoylethanolamide is a new possible pharmacological treatment for the inflammation associated with trauma. *Mini Rev Med Chem.* 2013 Feb;13(2):237-55. (I.F. **3.737**)
138. Impellizzeri D, Mazzone E, Paterniti I, **Esposito E**, Cuzzocrea S. Effect of fasudil, a selective inhibitor of Rho kinase activity, in the secondary injury associated with the experimental model of spinal cord trauma. *J Pharmacol Exp Ther.* 2012 Oct;343(1):21-33. (I.F. **4.402**)
139. Di Paola R, Impellizzeri D, Mondello P, Velardi E, Aloisi C, Cappellani A, **Esposito E**, Cuzzocrea S. Palmitoylethanolamide reduces early renal dysfunction and injury caused by experimental ischemia and reperfusion in mice. *Shock.* 2012 Oct;38(4):356-66. (I.F. **3.533**)
140. Ahmad A, Crupi R, Impellizzeri D, Campolo M, Marino A, **Esposito E**, Cuzzocrea S. Administration of palmitoylethanolamide (PEA) protects the neurovascular unit and reduces secondary injury after traumatic brain injury in mice. *Brain Behav Immun.* 2012 Nov;26(8):1310-21. (I.F. **19.227**)
141. **Esposito E**, Impellizzeri D, Mazzone E, Paterniti I, Cuzzocrea S. Neuroprotective activities of palmitoylethanolamide in an animal model of Parkinson's disease. *PLoS One.* 2012;7(8):e41880. (I.F. **3.58**)
142. Conte E, Genovese T, Gili E, **Esposito E**, Iemmolo M, Fruciano M, Fagone E, Pistorio MP, Crimi N, Cuzzocrea S, Vancheri C. Protective effects of thymosin β_4 in a mouse model of lung fibrosis. *Ann N Y Acad Sci.* 2012 Oct;1269:69-73. (I.F. **6.499**)

143. Ahmad A, Genovese T, Impellizzeri D, Crupi R, Velardi E, Marino A, **Esposito E**, Cuzzocrea S. Reduction of ischemic brain injury by administration of palmitoylethanolamide after transient middle cerebral artery occlusion in rats. *Brain Res.* 2012 Oct 5;1477:45-58. (I.F. **3.61**)
144. Campolo M, Di Paola R, Impellizzeri D, Crupi R, Morittu VM, Procopio A, Perri E, Britti D, Peli A, **Esposito E**, Cuzzocrea S. Effects of a polyphenol present in olive oil, oleuropein aglycone, in a murine model of intestinal ischemia/reperfusion injury. *J Leukoc Biol.* 2013 Feb;93(2):277-87. (I.F. **6.011**)
145. Crupi R, Paterniti I, Campolo M, Di Paola R, Cuzzocrea S, **Esposito E**. Exogenous T3 administration provides neuroprotection in a murine model of traumatic brain injury. *Pharmacol Res.* 2013 Apr;70(1):80-9. (I.F. **10.334**)
146. Di Paola R, Genovese T, Impellizzeri D, Ahmad A, Cuzzocrea S, **Esposito E**. The renal injury and inflammation caused by ischemia-reperfusion are reduced by genetic inhibition of TNF- α R1: a comparison with infliximab treatment. *Eur J Pharmacol.* 2013 Jan 30;700(1-3):134-46. (I.F. **5.195**)
147. Conte E, Genovese T, Gili E, **Esposito E**, Iemmolo M, Fruciano M, Fagone E, Pistorio MP, Crimi N, Cuzzocrea S, Vancheri C. Thymosin β 4 protects C57BL/6 mice from bleomycin-induced damage in the lung. *Eur J Clin Invest.* 2013 Mar;43(3):309-15. (I.F. **5.722**)
148. Finley A, Chen Z, **Esposito E**, Cuzzocrea S, Sabbadini R, Salvemini D. Sphingosine 1-phosphate mediates hyperalgesia via a neutrophil-dependent mechanism. *PLoS One.* 2013;8(1):e55255. (I.F. **3.58**)
149. Paterniti I, Impellizzeri D, Crupi R, Morabito R, Campolo M, **Esposito E**, Cuzzocrea S. Molecular evidence for the involvement of PPAR- δ and PPAR- γ in anti-inflammatory and neuroprotective activities of palmitoylethanolamide after spinal cord trauma. *J Neuroinflammation.* 2013 Feb 1;10:20. (I.F. **9.587**)
150. **Esposito E**, Cuzzocrea S. Palmitoylethanolamide in homeostatic and traumatic central nervous system injuries. *CNS Neurol Disord Drug Targets.* 2013 Feb 1;12(1):55-61. (I.F. **2.824**)
151. Doyle T, **Esposito E**, Bryant L, Cuzzocrea S, Salvemini D. NADPH-oxidase 2 activation promotes opioid-induced antinociceptive tolerance in mice. *Neuroscience.* 2013 Jun 25;241:1-9. (I.F. **3.708**)
152. Genovese T, Impellizzeri D, Ahmad A, Cornelius C, Campolo M, Cuzzocrea S, **Esposito E**. Post-ischaemic thyroid hormone treatment in a rat model of acute stroke. *Brain Res.* 2013 Jun 4;1513:92-102. (I.F. **3.61**)
153. Campolo M, Ahmad A, Crupi R, Impellizzeri D, Morabito R, **Esposito E**, Cuzzocrea S. Combination therapy with melatonin and dexamethasone in a mouse model of traumatic brain injury. *J Endocrinol.* 2013 Apr 29;217(3):291-301. (I.F. **4.669**)
154. Ahmad A, Crupi R, Campolo M, Genovese T, **Esposito E**, Cuzzocrea S. Absence of TLR4 reduces neurovascular unit and secondary inflammatory process after traumatic brain injury in mice. *PLoS One.* 2013;8(3):e57208. (I.F. **3.58**)
155. Little JW, Cuzzocrea S, Bryant L, **Esposito E**, Doyle T, Rausaria S, Neumann WL, Salvemini D. Spinal mitochondrial-derived peroxynitrite enhances neuroimmune activation during morphine hyperalgesia and antinociceptive tolerance. *Pain.* 2013 Jul;154(7):978-86. (I.F. **7.926**)
156. Crupi R, Paterniti I, Ahmad A, Campolo M, **Esposito E**, Cuzzocrea S. Effects of palmitoylethanolamide and luteolin in an animal model of anxiety/depression. *CNS Neurol Disord Drug Targets.* 2013 Jul 10. [Epub ahead of print] (I.F. **2.824**)
157. Paterniti I, Impellizzeri D, Di Paola R, Navarra M, Cuzzocrea S, **Esposito E**. A new co-ultramicrosized composite including palmitoylethanolamide and luteolin to prevent neuroinflammation in spinal cord injury. *J Neuroinflammation.* 2013 Jul 23;10:91. (I.F. **9.587**)
158. Janes K, Doyle T, Bryant L, **Esposito E**, Cuzzocrea S, Ryerse J, Bennett GJ, Salvemini D. Bioenergetic deficits in peripheral nerve sensory axons during chemotherapy-induced neuropathic pain resulting from peroxynitrite-mediated post-translational nitration of mitochondrial superoxide dismutase. *Pain.* 2013 Nov;154(11):2432-40. (I.F. **7.926**)
159. Campolo M, **Esposito E**, Ahmad A, Di Paola R, Wallace JL, Cuzzocrea S. A hydrogen sulfide-releasing cyclooxygenase inhibitor markedly accelerates recovery from experimental spinal cord injury. *FASEB J.* 2013 Nov;27(11):4489-99. (I.F. **5.834**)
160. Impellizzeri D, **Esposito E**, Di Paola R, Ahmad A, Campolo M, Peli A, Morittu VM, Britti D, Cuzzocrea S. Palmitoylethanolamide and luteolin ameliorate development of arthritis caused by injection of collagen type II in mice. *Arthritis Res Ther.* 2013 Nov 18;15(6):R192. [Epub ahead of print] PubMed PMID: 24246048. (I.F. **5.606**)
161. Polimeni G, **Esposito E**, Bevelacqua V, Guameri C, Cuzzocrea S. Role of melatonin supplementation in neurodegenerative disorders. *Front Biosci (Landmark Ed).* 2014 Jan 1;19:429-46. PubMed PMID: 24389194. (I.F. **3.115**)
162. Paterniti I, Impellizzeri D, Di Paola R, **Esposito E**, Gladman S, Yip P, Priestley JV, Michael-Titus AT, Cuzzocrea S. Docosahexaenoic acid

- attenuates the early inflammatory response following spinal cord injury in mice: in-vivo and in-vitro studies. *J Neuroinflammation*. 2014 Jan 10;11:6. (I.F. **9.587**)
163. Paterniti I, **Esposito E**, Cuzzocrea S. Phosphodiesterases as a New Therapeutic Targets for the Treatment of Spinal Cord Injury and Neurodegenerative Diseases. *Curr Med Chem*. 2014 Feb 16. [Epub ahead of print] PubMed PMID: 24533816. (I.F. **4.74**)
164. Impellizzeri D, **Esposito E**, Attley J, Cuzzocrea S. Targeting inflammation: new therapeutic approaches in chronic kidney disease (CKD). *Pharmacol Res*. 2014 Mar;81:91-102. (I.F. **10.334**)
165. Bruschetta G, Impellizzeri D, Morabito R, Marino A, Ahmad A, Spanò N, Spada GL, Cuzzocrea S, **Esposito E**. Pelagia noctiluca (Scyphozoa) crude venom injection elicits oxidative stress and inflammatory response in rats. *Mar Drugs*. 2014 Apr 10;12(4):2182-204. (I.F. **6.085**)
166. **Esposito E**, Cordaro M, Cuzzocrea S. Roles of fatty acid ethanolamides (FAE) in traumatic and ischemic brain injury. *Pharmacol Res*. 2014 May 27. pii: S1043-6618(14)00081-4. (I.F. **10.334**)
167. Janes K, Little JW, Li C, Bryant L, Chen C, Chen Z, Kamocki K, Doyle T, Snider A, **Esposito E**, Cuzzocrea S, Bieberich E, Obeid L, Petrache I, Nicol G, Neumann WL, Salvemini D. The Development and Maintenance of Paclitaxel-Induced Neuropathic Pain Requires Activation of the Sphingosine 1-Phosphate Receptor Subtype 1. *J Biol Chem*. 2014 May 29. pii: jbc.M114.569574. [Epub ahead of print] PubMed PMID: 24876379. (I.F. **5.486**)
168. Conte E, Iemmolo M, Fagone E, Gili E, Fruciano M, Genovese T, **Esposito E**, Cuzzocrea S, Vancheri C. Thymosin β 4 reduces IL-17-producing cells and IL-17 expression, and protects lungs from damage in bleomycin-treated mice. *Immunobiology*. 2014 Jun;219(6):425-31. (I.F. **3.152**)
169. Cordaro M, Impellizzeri D, Paterniti I, Bruschetta G, Siracusa R, De Stefano D, Cuzzocrea S, **Esposito E**. Neuroprotective effects of Co-ultraPEALut on secondary inflammatory process and autophagy involved in traumatic brain injury. *J Neurotrauma*. 2014 Jul 21. (I.F. **4.869**)
170. Paterniti I, Cordaro M, Campolo M, Siracusa R, Cornelius C, Navarra M, Cuzzocrea S, **Esposito E**. Neuroprotection by association of palmitoylethanolamide with luteolin in experimental Alzheimer's disease models: the control of neuroinflammation. *CNS Neurol Disord Drug Targets*. 2014;13(9):1530-41. (I.F. **2.824**)
171. Impellizzeri D, Bruschetta G, Cordaro M, Crupi R, Siracusa R, **Esposito E**, Cuzzocrea S. Micronized/ultramicrosized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain. *J Neuroinflammation*. 2014 Aug 28;11:136. (I.F. **9.587**)
172. Janes K, **Esposito E**, Doyle T, Cuzzocrea S, Tosh DK, Jacobson KA, Salvemini D. A3 adenosine receptor agonist prevents the development of paclitaxel-induced neuropathic pain by modulating spinal glial-restricted redox-dependent signaling pathways. *Pain*. 2014 Dec;155(12):2560-7. (I.F. **7.926**)
173. Petrosino S, Ahmad A, Marcolongo G, **Esposito E**, Allarà M, Verde R, Cuzzocrea S, Di Marzo V. Diacerein is a potent and selective inhibitor of palmitoylethanolamide inactivation with analgesic activity in a rat model of acute inflammatory pain. *Pharmacol Res*. 2015 Jan;91:9-14. (I.F. **10.334**)
174. Campolo M, **Esposito E**, Ahmad A, Di Paola R, Paterniti I, Cordaro M, Bruschetta G, Wallace JL, Cuzzocrea S. Hydrogen sulfide-releasing cyclooxygenase inhibitor ATB-346 enhances motor function and reduces cortical lesion volume following traumatic brain injury in mice. *J Neuroinflammation*. 2014 Dec 4;11(1):196. (I.F. **9.587**)
175. Impellizzeri D, Bruschetta G, Di Paola R, Ahmad A, Campolo M, Cuzzocrea S, **Esposito E**, Navarra M. The anti-inflammatory and antioxidant effects of bergamot juice extract (BJe) in an experimental model of inflammatory bowel disease. *Clin Nutr*. 2014 Nov 27. pii: S0261-5614(14)00293-3. (I.F. **7.643**)
176. Impellizzeri D, Bruschetta G, **Esposito E**, Cuzzocrea S. Emerging drugs for acute lung injury. *Expert Opin Emerg Drugs*. 2015 Mar;20(1):75-89. (I.F. **4.191**)
177. Impellizzeri D, Ahmad A, Bruschetta G, Di Paola R, Crupi R, Paterniti I, **Esposito E**, Cuzzocrea S. The anti-inflammatory effects of palmitoylethanolamide (PEA) on endotoxin-induced uveitis in rats. *Eur J Pharmacol*. 2015 Aug 15;761:28-35. (I.F. **5.195**)
178. Impellizzeri D, Bruschetta G, Ahmad A, Crupi R, Siracusa R, Di Paola R, Paterniti I, Prosdocimi M, **Esposito E**, Cuzzocrea S. Effects of palmitoylethanolamide and silymarin combination treatment in an animal model of kidney ischemia and reperfusion. *Eur J Pharmacol*. 2015 Sep

5;762:136-49. (I.F. **5.195**)

- 179.** : Impellizzeri D, Ahmad A, Di Paola R, Campolo M, Navarra M, **Esposito E**, Cuzzocrea S. Role of Toll like receptor 4 signaling pathway in the secondary damage induced by experimental spinal cord injury. *Immunobiology*. 2015 Sep;220(9):1039-49. (I.F. **3.152**)
- 180.** Di Cesare Mannelli L, Pacini A, Corti F, Boccella S, Luongo L, **Esposito E**, Cuzzocrea S, Maione S, Calignano A, Ghelardini C. Antineuropathic profile of N-palmitoylethanolamine in a rat model of oxaliplatin-induced neurotoxicity. *PLoS One*. 2015 Jun 3;10(6):e0128080. (I.F. **3.58**)
- 181.** Paterniti I, Cordaro M, Navarra M, **Esposito E**, Cuzzocrea S. Emerging pharmacotherapy for treatment of traumatic brain injury: targeting hypopituitarism and inflammation. *Expert Opin Emerg Drugs*. 2015;20(4):583-96. (I.F. **4.191**)
- 182.** Conte E, Iemmolo M, Fruciano M, Fagone E, Gili E, Genovese T, **Esposito E**, Cuzzocrea S, Vancheri C. Effects of thymosin β 4 and its N-terminal fragment Ac-SDKP on TGF- β -treated human lung fibroblasts and in the mouse model of bleomycin-induced lung fibrosis. *Expert Opin Biol Ther*. 2015;15 Suppl 1:S211-21. (I.F. **5.589**)
- 183.** : Siracusa R, Paterniti I, Bruschetta G, Cordaro M, Impellizzeri D, Crupi R, Cuzzocrea S, **Esposito E**. The Association of Palmitoylethanolamide with Luteolin Decreases Autophagy in Spinal Cord Injury. *Mol Neurobiol*. 2016 Aug;53(6):3783-3792. (I.F. **5.682**)
- 184.** Siracusa R, Paterniti I, Impellizzeri D, Cordaro M, Crupi R, Navarra M, Cuzzocrea S, **Esposito E**. The Association of Palmitoylethanolamide with Luteolin Decreases Neuroinflammation and Stimulates Autophagy in Parkinson's Disease Model. *CNS Neurol Disord Drug Targets*. 2015;14(10):1350-65. PubMed PMID:26295827. (I.F. **2.824**)
- 185.** Impellizzeri D, Talero E, Siracusa R, Alcaide A, Cordaro M, Maria Zubelia J, Bruschetta G, Crupi R, **Esposito E**, Cuzzocrea S, Motilva V. Protective effect of polyphenols in an inflammatory process associated with experimental pulmonary fibrosis in mice. *Br J Nutr*. 2015 Sep 28;114(6):853-65. (I.F. **4.125**)
- 186.** Cordaro M, Impellizzeri D, Bruschetta G, Siracusa R, Crupi R, Di Paola R, **Esposito E**, Cuzzocrea S. A novel protective formulation of Palmitoylethanolamide in experimental model of contrast agent induced nephropathy. *Toxicol Lett*. 2016 Jan 5;240(1):10-21. (I.F. **4.271**)
- 187.** Paterniti I, Di Paola R, Campolo M, Siracusa R, Cordaro M, Bruschetta G, Tremolada G, Maestroni A, Bandello F, **Esposito E**, Zerbini G, Cuzzocrea S. Palmitoylethanolamide treatment reduces retinal inflammation in streptozotocin-induced diabetic rats. *Eur J Pharmacol*. 2015 Dec 15;769:313-23. (I.F. **5.195**)
- 188.** : Casili G, Cordaro M, Impellizzeri D, Bruschetta G, Paterniti I, Cuzzocrea S, **Esposito E**. Dimethyl Fumarate Reduces Inflammatory Responses in Experimental Colitis. *J Crohns Colitis*. 2016 Apr;10(4):472-83. (I.F. **10.020**)
- 189.** Caltagirone C, Cisari C, Schievano C, Di Paola R, Cordaro M, Bruschetta G, **Esposito E**, Cuzzocrea S; Stroke Study Group. Co-ultramicrozoned Palmitoylethanolamide/Luteolin in the Treatment of Cerebral Ischemia: from Rodent to Man. *Transl Stroke Res*. 2016 Feb;7(1):54-69. (I.F. **6.800**)
- 190.** Di Paola R, Cordaro M, Crupi R, Siracusa R, Campolo M, Bruschetta G, Fusco R, Pugliatti P, **Esposito E**, Cuzzocrea S. Protective Effects of Ultramicrozoned Palmitoylethanolamide (PEA-um) in Myocardial Ischaemia and Reperfusion Injury in VIVO. *Shock*. 2016 Aug;46(2):202-13. (I.F. **3.533**)
- 191.** Cordaro M, Paterniti I, Siracusa R, Impellizzeri D, **Esposito E**, Cuzzocrea S. KU0063794, a Dual mTORC1 and mTORC2 Inhibitor, Reduces Neural Tissue Damage and Locomotor Impairment After Spinal Cord Injury in Mice. *Mol Neurobiol*. 2017 May;54(4):2415-2427. (I.F. **5.682**)
- 192.** Crupi R, Impellizzeri D, Bruschetta G, Cordaro M, Paterniti I, Siracusa R, Cuzzocrea S, **Esposito E**. Co-Ultramicrozoned Palmitoylethanolamide/Luteolin Promotes Neuronal Regeneration after Spinal Cord Injury. *Front Pharmacol*. 2016 Mar 8;7:47. (I.F. **5.988**)

193. **Esposito E**, Daniela Impellizzeri, Giuseppe Bruschetta, Michela Campolo, Rosalba Siracusa, Emrico Gugliandolo, Rosalia Crupi, Salvatore Cuzzocrea. A new co-micronized composite containing palmitoylethanolamide and polydatin shows superior oral efficacy compared to their association in a rat paw model of carrageenan-induced inflammation. *Eur J Pharmacol.* 2016 Jul 5;782:107-18. (I.F. **5.195**)
194. Paterniti I, Cordaro M, **Esposito E**, Cuzzocrea S. The antioxidative property of melatonin against brain ischemia. *Expert Rev Neurother.* 2016 Jul;16(7):841-8. Review. (IF **4.287**)
195. Di Paola R, Impellizzeri D, Fusco R, Cordaro M, Siracusa R, Crupi R, **Esposito E**, Cuzzocrea S. Ultramicronized palmitoylethanolamide (PEA-um(®)) in the treatment of idiopathic pulmonary fibrosis. *Pharmacol Res.* 2016 Sep;111:405-412. (I.F. **10.334**)
196. Impellizzeri D, Cordaro M, Campolo M, Gugliandolo E, **Esposito E**, Benedetto F, Cuzzocrea S, Navarra M. Anti-inflammatory and Antioxidant Effects of Flavonoid-Rich Fraction of Bergamot Juice (BJe) in a Mouse Model of Intestinal Ischemia/Reperfusion Injury. *Front Pharmacol.* 2016 Jul 15;7:203. (I.F. **5.988**)
197. Impellizzeri D, Di Paola R, Cordaro M, Gugliandolo E, Casili G, Morittu VM, Britti D, **Esposito E**, Cuzzocrea S. Adelmidrol, a palmitoylethanolamide analogue, as a new pharmacological treatment for the management of acute and chronic inflammation. *Biochem Pharmacol.* 2016 Nov 1;119:27-41. (I.F. **6.1**)
198. Cordaro M, Impellizzeri D, Gugliandolo E, Siracusa R, Crupi R, **Esposito E**, Cuzzocrea S. Adelmidrol, a Palmitoylethanolamide Analogue, as a New Pharmacological Treatment for the Management of Inflammatory Bowel Disease. *Mol Pharmacol.* 2016 Nov;90(5):549-561. (I.F. **5.682**)
199. Paterniti I, Campolo M, Cordaro M, Impellizzeri D, Siracusa R, Crupi R, **Esposito E**, Cuzzocrea S. PPAR- α Modulates the Anti-Inflammatory Effect of Melatonin in the Secondary Events of Spinal Cord Injury. *Mol Neurobiol.* 2017 Oct;54(8):5973-5987. (I.F. **5.682**)
200. Bertolino B, Crupi R, Impellizzeri D, Bruschetta G, Cordaro M, Siracusa R, **Esposito E**, Cuzzocrea S. Beneficial Effects of Co-Ultramicronized Palmitoylethanolamide/Luteolin in a Mouse Model of Autism and in a Case Report of Autism. *CNS Neurosci Ther.* 2017 Jan;23(1):87-98. (I.F. **7.035**)
201. Casili G, Impellizzeri D, Cordaro M, **Esposito E**, Cuzzocrea S. B-Cell Depletion with CD20 Antibodies as New Approach in the Treatment of Inflammatory and Immunological Events Associated with Spinal Cord Injury. *Neurotherapeutics.* 2016 Oct;13(4):880-894. (I.F. **6.088**)
202. Impellizzeri D, Campolo M, Bruschetta G, Crupi R, Cordaro M, Paterniti I, Cuzzocrea S, **Esposito E**. Traumatic Brain Injury Leads to Development of Parkinson's Disease Related Pathology in Mice. *Front Neurosci.* 2016 Oct 13;10:458. (I.F. **5.152**)
203. Cordaro M, Casili G, Paterniti I, Cuzzocrea S, **Esposito E**. Fumaric Acid Esters Attenuate Secondary Degeneration after Spinal Cord Injury. *J Neurotrauma.* 2017 Nov 1;34(21):3027-3040. (I.F. **4.869**)
204. Campolo M, Casili G, Biundo F, Crupi R, Cordaro M, Cuzzocrea S, **Esposito E**. The Neuroprotective Effect of Dimethyl Fumarate in an MPTP-Mouse Model of Parkinson's Disease: Involvement of Reactive Oxygen Species/Nuclear Factor- κ B/Nuclear Transcription Factor Related to NF-E2. Antioxid Redox Signal. 2017 Sep 10;27(8):453-471. (I.F. **7.468**)
205. Impellizzeri D, Cordaro M, Bruschetta G, Siracusa R, Crupi R, **Esposito E**, Cuzzocrea S. N-Palmitoylethanolamine-Oxazoline as a New Therapeutic Strategy to Control Neuroinflammation: Neuroprotective Effects in Experimental Models of Spinal Cord and Brain Injury. *J Neurotrauma.* 2017 Sep 15;34(18):2609-2623 (I.F. **4.869**)
206. Bruschetta G, Impellizzeri D, Campolo M, Casili G, Di Paola R, Paterniti I, **Esposito E**, Cuzzocrea S. FeTPPS Reduces Secondary Damage and Improves Neurobehavioral Functions after Traumatic Brain Injury. *Front Neurosci.* 2017 Feb 7;11:6. (I.F. **5.152**)
207. Siracusa R, Paterniti I, Cordaro M, Crupi R, Bruschetta G, Campolo M, Cuzzocrea S, **Esposito E**. Neuroprotective Effects of Temsirolimus in Animal Models of Parkinson's Disease. *Mol Neurobiol.* 2017 Mar 29. (I.F. **5.682**)

208. Paterniti I, Campolo M, Siracusa R, Cordaro M, Di Paola R, Calabrese V, Navarra M, Cuzzocrea S, **Esposito E**. Liver X receptors activation, through TO901317 binding, reduces neuroinflammation in Parkinson's disease. *PLoS One*. 2017 Apr 3;12(4):e0174470. (I.F. **3.58**)
209. Granata G, Paterniti I, Geraci C, Cunsolo F, **Esposito E**, Cordaro M, Blanco AR, Cuzzocrea S, Consoli GML. Potential Eye Drop Based on a Calix[4]arene Nanoassembly for Curcumin Delivery: Enhanced Drug Solubility, Stability, and Anti-Inflammatory Effect. *Mol Pharm*. 2017 May 1;14(5):1610-1622. (I.F. **5.364**)
210. Cordaro M, Impellizzeri D, Siracusa R, Gugliandolo E, Fusco R, Inferred A, **Esposito E**, Di Paola R, Cuzzocrea S. Effects of a co-micronized composite containing palmitoylethanolamide and polydatin in an experimental model of benign prostatic hyperplasia. *Toxicol Appl Pharmacol*. 2017 Aug 15;329:231-240. (I.F. **4.46**)
211. Petrosino S, Campolo M, Impellizzeri D, Paterniti I, Allarà M, Gugliandolo E, D'Amico R, Siracusa R, Cordaro M, **Esposito E**, Di Marzo V, Cuzzocrea S. 2-Pentadecyl-2-Oxazoline, the Oxazoline of Pea, Modulates Carrageenan-Induced Acute Inflammation. *Front Pharmacol*. 2017 May 30;8:308. (I.F. **5.988**)
212. Siracusa R, Impellizzeri D, Cordaro M, Crupi R, **Esposito E**, Petrosino S, Cuzzocrea S. Anti-Inflammatory and Neuroprotective Effects of Co-UltraPEALut in a Mouse Model of Vascular Dementia. *Front Neurol*. 2017 Jun 6;8:233. (I.F. **4.086**)
213. Cross J, Stenton GR, Harwig C, Szabo C, Genovese T, Di Paola R, **Esposito E**, Cuzzocrea S, Mackenzie LF. AQX-1125, small molecule SHIP1 activator inhibits bleomycin-induced pulmonary fibrosis. *Br J Pharmacol*. 2017 Sep;174(18):3045-3057. (I.F. **9.47**)
214. Paterniti I, Impellizzeri D, Cordaro M, Siracusa R, Bisignano C, Gugliandolo E, Carughi A, **Esposito E**, Mandalari G, Cuzzocrea S. The Anti-Inflammatory and Antioxidant Potential of Pistachios (*Pistacia vera* L.) In Vitro and In Vivo. *Nutrients*. 2017 Aug 22;9(8). pii: E915. (I.F. **6.706**)
215. Mirshafiey A, Taeb M, Mortazavi-Jahromi SS, Jafarnejhad-Ansariha F, Rehm BHA, **Esposito E**, Cuzzocrea S, Matsuo H. Introduction of β -d-mannuronic acid (M2000) as a novel NSAID with immunosuppressive property based on COX-1/COX-2 activity and gene expression. *Pharmacol Rep*. 2017 Oct;69(5):1067-1072. (I.F. **3.919**)
216. Caffo M, **Esposito E**, Barresi V, Caruso G, Cardali SM, Rinaldi M, Mallamace R, Campolo M, Casili G, Conti A, Germanò A, Cuzzocrea S, Minutoli L. Modulation of Dkk-3 and claudin-5 as new therapeutic strategy in the treatment of meningiomas. *Oncotarget*. 2017 Aug 7;8(40):68280-68290. (I.F. **5.168**)
217. Campolo M, Casili G, Lanza M, Filippone A, Paterniti I, Cuzzocrea S, **Esposito E**. Multiple mechanisms of dimethyl fumarate in amyloid β -induced neurotoxicity in human neuronal cells. *J Cell Mol Med*. 2018 Feb;22(2):1081-1094. (I.F. **5.31**)
218. Paterniti I, **Esposito E**, Cuzzocrea S. An In Vivo Compression Model of Spinal Cord Injury. *Methods Mol Biol*. 2018;1727:379-384. (I.F. **1.372**)
219. Campolo M, **Esposito E**, Cuzzocrea S. A Controlled Cortical Impact Preclinical Model of Traumatic Brain Injury. *Methods Mol Biol*. 2018;1727:385-391. (I.F. **1.372**)
220. Crupi R, Di Paola R, **Esposito E**, Cuzzocrea S. Middle Cerebral Artery Occlusion by an Intraluminal Suture Method. *Methods Mol Biol*. 2018;1727:393-401. (I.F. **1.372**)
221. Cuzzocrea S, Doyle T, Campolo M, Paterniti I, **Esposito E**, Farr S, Salvemini D. Sphingosine 1-phosphate receptor subtype 1 (S1PR1) as a therapeutic target for brain trauma. *J Neurotrauma*. 2018 Jan 8. doi: 10.1089/neu.2017.5391. (I.F. **4.869**)
222. Siracusa R, Paterniti I, Cordaro M, Crupi R, Bruschetta G, Campolo M, Cuzzocrea S, **Esposito E**. Neuroprotective Effects of Temsirolimus in Animal Models of Parkinson's Disease. *Mol Neurobiol*. 2018 Mar;55(3):2403-2419. (I.F. **5.682**)

223. Jafamezhad-Ansariha F, Yekaninejad MS, Jamshidi AR, Mansouri R, Vojdani M, Mahmoudi M, Fattahi MJ, Hashemi SN, Rehm BHA, Matsuo H, Esposito E, Cuzzocrea S, Mirshafiey A. The effects of β -D-mannuronic acid (M2000), as a novel NSAID, on COX1 and COX2 activities and gene expression in ankylosing spondylitis patients and the murine monocyte/macrophage, J774 cell line. *Inflammopharmacology*. 2018 Apr;26(2):375-384. (I.F. **5.093**)
224. Cuzzocrea S, Doyle T, Campolo M, Paterniti I, **Esposito E**, Farr SA, Salvemini D. Sphingosine 1-Phosphate Receptor Subtype 1 as a Therapeutic Target for Brain Trauma. *J Neurotrauma*. 2018 Jul 1;35(13):1452-1466. (I.F. **4.869**)
225. Casili G, Campolo M, Paterniti I, Lanza M, Filippone A, Cuzzocrea S, Esposito E. Dimethyl Fumarate Attenuates Neuroinflammation and Neurobehavioral Deficits Induced by Experimental Traumatic Brain Injury. *J Neurotrauma*. 2018 Jul 1;35(13):1437-1451. . (I.F. **4.869**)
226. : Wahlman C, Doyle TM, Little JW, Luongo L, Janes K, Chen Z, **Esposito E**, Tosh DK, Cuzzocrea S, Jacobson KA, Salvemini D. Chemotherapy-induced pain is promoted by enhanced spinal adenosine kinase levels through astrocyte-dependent mechanisms. *Pain*. 2018 Jun;159(6):1025-1034. (I.F. **7.926**)
227. Petrosino S, Cordaro M, Verde R, Schiano Moriello A, Marcolongo G, Schievano C, Siracusa R, Piscitelli F, Peritore AF, Crupi R, Impellizzeri D, **Esposito E**, Cuzzocrea S, Di Marzo V. Oral Ultramicrosized Palmitoylethanolamide: Plasma and Tissue Levels and Spinal Anti-hyperalgesic Effect. *Front Pharmacol*. 2018 Mar 20;9:249. (I.F. **5.988**)
228. Paterniti I, Campolo M, Cordaro M, Siracusa R, Filippone A, **Esposito E**, Cuzzocrea S. Effects of different natural extracts in an experimental model of benign prostatic hyperplasia (BPH). *Inflamm Res*. 2018 Jul;67(7):617-626. (I.F. **6.986**)
229. Mirshafiey A, Mortazavi-Jahromi SS, Taeb M, Cuzzocrea S, **Esposito E**. Evaluation of the Effect of α -L-Guluronic Acid (G2013) on COX-1, COX-2 Activity and Gene Expression for Introducing this Drug as a Novel NSAID with Immunomodulatory Property. *Recent Pat Inflamm Allergy Drug Discov*. 2018;12(2):162-168. (I.F. **5.90**)
230. **Esposito E**, Campolo M, Casili G, Lanza M, Franco D, Filippone A, Peritore AF, Cuzzocrea S. Protective Effects of Xyloglucan in Association with the Polysaccharide Gelose in an Experimental Model of Gastroenteritis and Urinary Tract Infections. *Int J Mol Sci*. 2018 Jun 22;19(7). (I.F. **6.208**)
231. Bartolucci ML, Marini I, Bortolotti F, Impellizzeri D, Di Paola R, Bruschetta G, Crupi R, Portelli M, Militi A, Oteri G, Esposito E, Cuzzocrea S. Micronized palmitoylethanolamide reduces joint pain and glial cell activation. *Inflamm Res*. 2018 Oct;67(10):891-901. (I.F. **6.922**)
232. Lanza M, Campolo M, Casili G, Filippone A, Paterniti I, Cuzzocrea S, **Esposito E**. Sodium Butyrate Exerts Neuroprotective Effects in Spinal Cord Injury. *Mol Neurobiol*. 2018 Sep 18. doi: 10.1007/s12035-018-1347-7. (I.F. **5.59**)
233. **Esposito E**, Campolo M, Casili G, Lanza M, Filippone A, Peritore AF, Cuzzocrea S. Effect of pea protein plus grape seed dry extract on a murine model of *Candida albicans* induced vaginitis. *Future Microbiol*. 2018 Sep;13:1375-1382. (I.F. **2.49**)
234. Casili G, Caffo M, Campolo M, Barresi V, Caruso G, Cardali SM, Lanza M, Mallamace R, Filippone A, Conti A, Germanò A, Cuzzocrea S, **Esposito E**. TLR-4/Wnt modulation as new therapeutic strategy in the treatment of glioblastomas. *Oncotarget*. 2018 Dec 25;9(101):37564-37580. doi: 10.18632/oncotarget.26500. (i.F. **5.168**)
235. Campolo M, Paterniti I, Siracusa R, Filippone A, **Esposito E**, Cuzzocrea S. TLR4 absence reduces neuroinflammation and inflammasome activation in Parkinson's diseases in vivo model. *Brain Behav Immun*. 2019 Feb;76:236-247. doi:10.1016/j.bbi.2018.12.003. (I.F. **7.217**)
236. Casili G, Lanza M, Filippone A, Campolo M, Paterniti I, Cuzzocrea S, **Esposito E**. Dimethyl fumarate alleviates the nitroglycerin (NTG)-induced migraine in mice. *J Neuroinflammation*. 2020 Feb 17;17(1):59. doi: 10.1186/s12974-020-01736-1. (I.F. **9.587**)

237. Scuderi SA, Ardizzone A, Paterniti I, **Esposito E**, Campolo M. Antioxidant and Anti-inflammatory Effect of Nrf2 Inducer Dimethyl Fumarate in Neurodegenerative Diseases. *Antioxidants (Basel)*. 2020 Jul 17;9(7):630. doi: 10.3390/antiox9070630. (I.F. **6.675**)
238. : Ardizzone A, Scuderi SA, Giuffrida D, Colarossi C, Puglisi C, Campolo M, Cuzzocrea S, **Esposito E**, Paterniti I. Role of Fibroblast Growth Factors Receptors (FGFRs) in Brain Tumors, Focus on Astrocytoma and Glioblastoma. *Cancers (Basel)*. 2020 Dec 18;12(12):3825. doi: 10.3390/cancers12123825. (I.F. **6.575**)
239. Casili G, Lanza M, Campolo M, Messina S, Scuderi S, Ardizzone A, Filippone A, Paterniti I, Cuzzocrea S, **Esposito E**. Therapeutic potential of flavonoids in the treatment of chronic venous insufficiency. *Vascul Pharmacol*. 2021 Apr;137:106825. doi: 10.1016/j.vph.2020.106825. (I.F. **5.738**)
240. Campolo M, Filippone A, Biondo C, Mancuso G, Casili G, Lanza M, Cuzzocrea S, **Esposito E**, Paterniti I. TLR7/8 in the Pathogenesis of Parkinson's Disease. *Int J Mol Sci*. 2020 Dec 9;21(24):9384. doi: 10.3390/ijms21249384. (I.F. **6.208**)
241. Filippone A, Lanza M, Campolo M, Casili G, Paterniti I, Cuzzocrea S, **Esposito E**. The Anti-Inflammatory and Antioxidant Effects of Sodium Propionate. *Int J Mol Sci*. 2020 Apr 24;21(8):3026. doi: 10.3390/ijms21083026. (I.F. **6.208**)
242. Campolo M, Lanza M, Casili G, Paterniti I, Filippone A, Caffo M, Cardali SM, Puliafito I, Colarossi C, Raciti G, Cuzzocrea S, **Esposito E**. TAK1 Inhibitor Enhances the Therapeutic Treatment for Glioblastoma. *Cancers (Basel)*. 2020 Dec 25;13(1):41. doi: 10.3390/cancers13010041. (I.F. **6.575**)
243. Casili G, Ardizzone A, Lanza M, Gugliandolo E, Portelli M, Militi A, Cuzzocrea S, **Esposito E**, Paterniti I. Treatment with Luteolin Improves Lipopolysaccharide-Induced Periodontal Diseases in Rats. *Biomedicines*. 2020 Oct 21;8(10):442. doi: 10.3390/biomedicines8100442. (I.F. **4.757**)
244. Colombo G, Clemente N, Zito A, Bracci C, Colombo FS, Sangaletti S, Jachetti E, Ribaldone DG, Caviglia GP, Pastorelli L, De Andrea M, Naviglio S, Lucafò M, Stocco G, Grolla AA, Campolo M, Casili G, Cuzzocrea S, **Esposito E**, Malavasi F, Genazzani AA, Porta C, Travelli C. Neutralization of extracellular NAMPT (nicotinamide phosphoribosyltransferase) ameliorates experimental murine colitis. *J Mol Med (Berl)*. 2020 Apr;98(4):595-612. doi: 10.1007/s00109-020-01892-0. Epub 2020 Apr 27. (I.F. **5.606**)
245. Lanza M, Casili G, Torre GL, Giuffrida D, Rotondo A, **Esposito E**, Ardizzone A, Rando R, Bartolomeo G, Albergamo A, Vadalà R, Salvo A. Properties of a New Food Supplement Containing Actinia equina Extract. *Antioxidants (Basel)*. 2020 Oct 1;9(10):945. doi: 10.3390/antiox9100945. (I.F. **7.675**)
246. Calabrese G, Petralia S, Fabbi C, Forte S, Franco D, Guglielmino S, **Esposito E**, Cuzzocrea S, Traina F, Conoci S. Au, Pd and maghemite nanofunctionalized hydroxyapatite scaffolds for bone regeneration. *Regen Biomater*. 2020 Aug 27;7(5):461-469. doi: 10.1093/rb/rbaa033. eCollection 2020 Oct. (I.F. **5.763**)
247. **Esposito E**, Campolo M, Casili G, Lanza M, Franco D, Fazio E, Filippone A, Paterniti I, Cuzzocrea S. Efficacy of Xyloglucan against Escherichia coli Extraintestinal Urinary Tract Infection: An in vivo Study. *Microb Physiol*. 2020;30(1-6):50-60. doi: 10.1159/000510874. Epub 2020 Oct 16. (I.F. **2.21**)
248. Modulation of NLRP3 Inflammasome Attenuated Inflammatory Response Associated to Diarrhea-Predominant Irritable Bowel Syndrome. Scuderi SA, Casili G, Lanza M, Filippone A, Paterniti I, **Esposito E**, Campolo M. *Biomedicines*. 2020 Nov 20;8(11):519. doi: 10.3390/biomedicines8110519. (I.F. **4.757**)
249. Campolo M, Lanza M, Filippone A, Paterniti I, Casili G, Scuderi SA, Ardizzone A, Cuzzocrea S, **Esposito E**. Evaluation of a Product Containing Xyloglucan and Pea Protein on Skin Barrier Permeability. *Skin Pharmacol Physiol*. 2020;33(4):231-236. doi: 10.1159/000509372. Epub 2020 Aug 26. (I.F. **2.21**)
250. : Giannetto A, **Esposito E**, Lanza M, Oliva S, Riolo K, Di Pietro S, Abbate JM, Briguglio G, Cassata G, Cicero L, Macrì F. Protein Hydrolysates from Anchovy (*Engraulis encrasicolus*) Waste: In Vitro and In Vivo Biological Activities. *Mar Drugs*. 2020 Jan 28;18(2):86. doi: 10.3390/md18020086. (I.F. **6.085**)
251. Casili G, Lanza M, Campolo M, Siracusa R, Paterniti I, Ardizzone A, Scuderi SA, Cuzzocrea S, **Esposito E**. Synergic Therapeutic Potential of PEA-

- Um Treatment and NAAA Enzyme Silencing In the Management of Neuroinflammation. *Int J Mol Sci.* 2020 Oct 11;21(20):7486. doi: 10.3390/ijms21207486. (I.F. **6.208**)
252. Filippone A, Consoli GML, Granata G, Casili G, Lanza M, Ardizzone A, Cuzzocrea S, **Esposito E**, Paterniti I. Topical Delivery of Curcumin by Choline-Calix[4]arene-Based Nanohydrogel Improves Its Therapeutic Effect on a Psoriasis Mouse Model. *Int J Mol Sci.* 2020 Jul 17;21(14):5053. doi: 10.3390/ijms21145053. (I.F. **6.208**)
253. Campolo M, Casili G, Paterniti I, Filippone A, Lanza M, Ardizzone A, Scuderi SA, Cuzzocrea S, **Esposito E**. Effect of a Product Containing Xyloglucan and Pea Protein on a Murine Model of Atopic Dermatitis. *Int J Mol Sci.* 2020 May 19;21(10):3596. doi: 10.3390/ijms21103596. (I.F. **6.208**)
254. Casili G, Lanza M, Scuderi SA, Messina S, Paterniti I, Campolo M, **Esposito E**. The Inhibition of Prolyl Oligopeptidase as New Target to Counteract Chronic Venous Insufficiency: Findings in a Mouse Model. *Biomedicines.* 2020 Dec 13;8(12):604. doi: 10.3390/biomedicines8120604. (I.F. **4.757**)
255. Doyle TM, Janes K, Chen Z, Grace PM, **Esposito E**, Cuzzocrea S, Largent-Milnes TM, Neumann WL, Watkins LR, Spiegel S, Vanderah TW, Salvemini D. Activation of sphingosine-1-phosphate receptor subtype 1 in the central nervous system contributes to morphine-induced hyperalgesia and antinociceptive tolerance in rodents. *Pain.* 2020 Sep 1;161(9):2107-2118. doi: 10.1097/j.pain.0000000000001888. (I.F. **7.926**)
256. Bianconi M, Ceriotti L, Cuzzocrea S, **Esposito E**, Pressi G, Sgaravatti E, Bertaiola O, Guarnerio C, Barbieri E, Semenzato A, Negri S, Comisso M, Avesani L, Guzzo F. Red Carrot Cells Cultured in vitro Are Effective, Stable, and Safe Ingredients for Skin Care, Nutraceutical, and Food Applications. *Front Bioeng Biotechnol.* 2020 Oct 21;8:575079. doi: 10.3389/fbioe.2020.575079. eCollection 2020. (I.F. **6.064**)
257. Farr SA, Cuzzocrea S, **Esposito E**, Campolo M, Niehoff ML, Doyle TM, Salvemini D. Adenosine A3 receptor as a novel therapeutic target to reduce secondary events and improve neurocognitive functions following traumatic brain injury. *J Neuroinflammation.* 2020 Nov 12;17(1):339. doi: 10.1186/s12974-020-02009-7. (I.F. **9.587**)
258. Casili G, Campolo M, Lanza M, Filippone A, Scuderi S, Messina S, Ardizzone A, **Esposito E**, Paterniti I. Role of ABT888, a Novel Poly(ADP-Ribose) Polymerase (PARP) Inhibitor in Countering Autophagy and Apoptotic Processes Associated to Spinal Cord Injury. *Mol Neurobiol.* 2020 Nov;57(11):4394-4407. doi: 10.1007/s12035-020-02033-x. (I.F. **5.682**)
259. Filippone A, Lanza M, Campolo M, Casili G, Paterniti I, Cuzzocrea S, **Esposito E**. Protective effect of sodium propionate in Abeta(1-42) -induced neurotoxicity and spinal cord trauma. *Neuropharmacology.* 2020 Apr;166:107977. doi: 10.1016/j.neuropharm.2020.107977. (I.F. **5.273**)
260. Basilotta R, Mannino D, Filippone A, Casili G, Prestifilippo A, Colarossi L, Raciti G, **Esposito E**, Campolo M. Role of Calixarene in Chemotherapy Delivery Strategies. *Molecules.* 2021 Jun 29;26(13):3963. doi: 10.3390/molecules26133963. (I.F. **4.927**)
261. Lanza M, Casili G, Campolo M, Paterniti I, Colarossi C, Mare M, Giuffrida R, Caffo M, **Esposito E**, Cuzzocrea S. Immunomodulatory Effect of Microglia-Released Cytokines in Gliomas. *Brain Sci.* 2021 Apr 7;11(4):466. doi: 10.3390/brainsci11040466. (I.F. **3.33**)
262. Ardizzone A, Calabrese G, Campolo M, Filippone A, Giuffrida D, Esposito F, Colarossi C, Cuzzocrea S, **Esposito E**, Paterniti I. Role of miRNA-19a in Cancer Diagnosis and Poor Prognosis. *Int J Mol Sci.* 2021 Apr 29;22(9):4697. doi: 10.3390/ijms22094697. (I.F. **6.208**)
263. Nocito G, Calabrese G, Forte S, Petralia S, Puglisi C, Campolo M, **Esposito E**, Conoci S. Carbon Dots as Promising Tools for Cancer Diagnosis and Therapy. *Cancers (Basel).* 2021 Apr 21;13(9):1991. doi: 10.3390/cancers13091991. (I.F. **6.57**)
264. Post-Mastectomy Pain: An Updated Overview on Risk Factors, Predictors, and Markers. Calapai M, **Esposito E**, Puzzo L, Vecchio DA, Blandino R, Bova G, Quattrone D, Mannucci C, Ammendola I, Mondello C, Gangemi S, Calapai G, Cardia L. *Life (Basel).* 2021 Sep 29;11(10):1026. doi: 10.3390/life11101026. (I.F. **3.25**)
265. Campolo M, Lanza M, Paterniti I, Filippone A, Ardizzone A, Casili G, Scuderi SA, Puglisi C, Mare M, Memeo L, Cuzzocrea S, **Esposito E**. PEA-OXA Mitigates Oxaliplatin-Induced Painful Neuropathy through NF- κ B/Nrf-2 Axis. *Int J Mol Sci.* 2021 Apr 10;22(8):3927. doi: 10.3390/ijms22083927. (I.F.

6.208).

266. Scuderi SA, Lanza M, Casili G, Esposito F, Colarossi C, Giuffrida D, Irene P, Cuzzocrea S, **Esposito E**, Campolo M. TBK1 Inhibitor Exerts Antiproliferative Effect on Glioblastoma Multiforme Cells. *Oncol Res.* 2021 Sep 7;28(7):779-790. doi: 10.3727/096504021X16161478258040. (I.F. **5.574**)
267. Campolo M, Crupi R, Cordaro M, Cardali SM, Ardizzone A, Casili G, Scuderi SA, Siracusa R, **Esposito E**, Conti A, Cuzzocrea S. Co-Ultra PEALut Enhances Endogenous Repair Response Following Moderate Traumatic Brain Injury. *Int J Mol Sci.* 2021 Aug 13;22(16):8717. doi: 10.3390/ijms22168717. (I.F. **6.208**).
268. : Casili G, Lanza M, Campolo M, Messina S, Scuderi S, Ardizzone A, Filippone A, Paterniti I, Cuzzocrea S, **Esposito E**. Therapeutic potential of flavonoids in the treatment of chronic venous insufficiency. *Vascul Pharmacol.* 2021 Apr;137:106825. doi: 10.1016/j.vph.2020.106825. (I.F. **5.738**)
269. : Scuderi SA, Casili G, Basilotta R, Lanza M, Filippone A, Raciti G, Puliafito I, Colarossi L, **Esposito E**, Paterniti I. NLRP3 Inflammasome Inhibitor BAY-117082 Reduces Oral Squamous Cell Carcinoma Progression. *Int J Mol Sci.* 2021 Oct 15;22(20):11108. doi: 10.3390/ijms222011108. (I.F. **6.208**).
270. Ardizzone A, Fusco R, Casili G, Lanza M, Impellizzeri D, **Esposito E**, Cuzzocrea S. Effect of Ultra-Micronized-Palmitoylethanolamide and Acetyl-L-Carnitine on Experimental Model of Inflammatory Pain. *Int J Mol Sci.* 2021 Feb 17;22(4):1967. doi: 10.3390/ijms22041967. (I.F. **6.208**).
271. Filippone A, Casili G, Ardizzone A, Lanza M, Mannino D, Paterniti I, **Esposito E**, Campolo M. Inhibition of Prolyl Oligopeptidase Prevents Consequences of Reperfusion following Intestinal Ischemia. *Biomedicines.* 2021 Sep 29;9(10):1354. doi: 10.3390/biomedicines9101354. (I.F. **4.75**)
272. Paterniti I, Scuderi SA, Casili G, Lanza M, Mare M, Giuffrida R, Colarossi C, Portelli M, Cuzzocrea S, **Esposito E**. Poly (ADP-Ribose) Polymerase Inhibitor, ABT888, Improved Cisplatin Effect in Human Oral Cell Carcinoma. *Biomedicines.* 2021 Jul 2;9(7):771. doi: 10.3390/biomedicines9070771. (I.F. **4.75**)
273. Scuderi SA, Casili G, Ardizzone A, Forte S, Colarossi L, Sava S, Paterniti I, **Esposito E**, Cuzzocrea S, Campolo M. KYP-2047, an Inhibitor of Prolyl-Oligopeptidase, Reduces Glioblastoma Proliferation through Angiogenesis and Apoptosis Modulation. *Cancers (Basel).* 2021 Jul 9;13(14):3444. doi: 10.3390/cancers13143444. (I.F. **6.57**)
274. Scuderi SA, Casili G, Filippone A, Lanza M, Basilotta R, Giuffrida R, Munaò S, Colarossi L, Capra AP, **Esposito E**, Paterniti I. Beneficial effect of KYP-2047, a propyl-oligopeptidase inhibitor, on oral squamous cell carcinoma. *Oncotarget.* 2021 Dec 7;12(25):2459-2473. doi: 10.18632/oncotarget.28147. (I.F. **5.168**)
275. Casili G, Ardizzone A, Basilotta R, Lanza M, Filippone A, Paterniti I, **Esposito E**, Campolo M. The Protective Role of Prolyl Oligopeptidase (POP) Inhibition in Kidney Injury Induced by Renal Ischemia-Reperfusion. *Int J Mol Sci.* 2021 Nov 2;22(21):11886. doi: 10.3390/ijms222111886. (I.F. **6.208**).
276. Casili G, Scuderi SA, Lanza M, Filippone A, Basilotta R, Mannino D, Campolo M, **Esposito E**, Paterniti I. The protective role of prolyl oligopeptidase (POP) inhibition in acute lung injury induced by intestinal ischemia-reperfusion. *Oncotarget.* 2021 Aug 17;12(17):1663-1676. doi: 10.18632/oncotarget.28041. (I.F. **5.168**)
277. Campolo M, Casili G, Lanza M, Filippone A, Cordaro M, Ardizzone A, Scuderi SA, Cuzzocrea S, **Esposito E**, Paterniti I. The inhibition of mammalian target of rapamycin (mTOR) in improving inflammatory response after traumatic brain injury. *J Cell Mol Med.* 2021 Aug;25(16):7855-7866. doi: 10.1111/jcmm.16702. (I.F. **5.29**)
278. Lanza M, Casili G, Filippone A, Campolo M, Paterniti I, Cuzzocrea S, **Esposito E**. Evaluating the Protective Properties of a Xyloglucan-Based Nasal Spray in a Mouse Model of Allergic Rhinitis. *Int J Mol Sci.* 2021 Sep 28;22(19):10472. doi: 10.3390/ijms221910472. (I.F. **6.208**).
279. Calabrese G, Ardizzone A, Campolo M, Conoci S, **Esposito E**, Paterniti I. Beneficial Effect of Tempol, a Membrane-Permeable Radical Scavenger,

- on Inflammation and Osteoarthritis in In Vitro Models. *Biomolecules*. 2021 Feb 25;11(3):352. doi: 10.3390/biom11030352. (I.F. **6.04**)
- 280.** Lanza M, Filippone A, Ardizzone A, Casili G, Paterniti I, **Esposito E**, Campolo M. SCFA Treatment Alleviates Pathological Signs of Migraine and Related Intestinal Alterations in a Mouse Model of NTG-Induced Migraine. *Cells*. 2021 Oct 14;10(10):2756. doi: 10.3390/cells10102756. (I.F. **7.66**).
- 281.** Filippone A, Esposito E, Mannino D, Lyssenko N, Praticò D. The contribution of altered neuronal autophagy to neurodegeneration. *Pharmacol Ther*. 2022 Mar 26;238:108178. doi: 10.1016/j.pharmthera.2022.108178. (I.F. **13.4**)
- 282.** Scuderi SA, Calabrese G, Paterniti I, Campolo M, Lanza M, Capra AP, Pantaleo L, Munaò S, Colarossi L, Forte S, Cuzzocrea S, Esposito E. The Biological Function of MicroRNAs in Bone Tumors. *Int J Mol Sci*. 2022 Feb 21;23(4):2348. doi: 10.3390/ijms23042348. (I.F. **6.208**).
- 283.** Basilotta R, Lanza M, Casili G, Chisari G, Munao S, Colarossi L, Cucinotta L, Campolo M, Esposito E, Paterniti I. Potential Therapeutic Effects of PPAR Ligands in Glioblastoma. *Cells*. 2022 Feb 10;11(4):621. doi: 10.3390/cells11040621. (I.F. **7.66**).
- 284.** Scuderi SA, Casili G, Lanza M, Ardizzone A, Pantaleo L, Campolo M, Paterniti I, Cucinotta L, Cuzzocrea S, Esposito E. Efficacy of a Product Containing Xyloglucan and Pea Protein on Intestinal Barrier Function in a Partial Restraint Stress Animal Model. *Int J Mol Sci*. 2022 Feb 18;23(4):2269. doi: 10.3390/ijms23042269. (I.F. **6.208**).
- 285.** Scuderi SA, Cucinotta L, Filippone A, Lanza M, Campolo M, Paterniti I, Esposito E. Effect of Melatonin on Psoriatic Phenotype in Human Reconstructed Skin Model. *Biomedicines* 2022, 10(4), 752; <https://doi.org/10.3390/biomedicines10040752>. (I.F. **4.75**).
- 286.** Ardizzone A, Bova V, Casili G, Filippone A, Campolo M, Lanza M, Esposito E, Paterniti I. SUN11602, a bFGF mimetic, modulated neuroinflammation, apoptosis and calcium-binding proteins in an in vivo model of MPT-induced nigrostriatal degeneration. *J Neuroinflammation* 2022, Apr;14(4):521-525. doi: 10.1016/j.cptl.2022.03.013. (I.F. **9.587**)
- 287.** Ardizzone A, Capra AP, Campolo M, Filippone A, Esposito E, Briuglia S. Neurofibromatosis: New Clinical Challenges in the Era of COVID-19. *Biomedicines*. 2022;10(5):940. Published 2022 Apr 19. doi:10.3390/biomedicines10050940. (I.F. **4.75**)
- 288.** Campolo M, Gallo G, Roviello F, Ardizzone A, La Torre M, Filippone A, Lanza M, Cuzzocrea S, Siroli L, Esposito E. Evaluation of a Gel Containing a *Propionibacterium* Extract in an In Vivo Model of Wound Healing. *Int J Mol Sci*. 2022 Apr 24;23(9):4708. doi: 10.3390/ijms23094708. (I.F. **6.208**).
- 289.** Lanza M, Filippone A, Casili G, Giuffrè L, Scuderi SA, Paterniti I, Campolo M, Cuzzocrea S, Esposito E. Supplementation with SCFAs Re-Establishes Microbiota Composition and Attenuates Hyperalgesia and Pain in a Mouse Model of NTG-Induced Migraine. *Int J Mol Sci*. 2022 Apr 27;23(9):4847. doi: 10.3390/ijms23094847. (I.F. **6.208**).
- 290.** Ardizzone A, Lanza M, Casili G, et al. Efficacy of a Novel Therapeutic, Based on Natural Ingredients and Probiotics, in a Murine Model of Multiple Food Intolerance and Maldigestion. *Nutrients*. 2022;14(11):2251. Published 2022 May 27. doi:10.3390/nu14112251. (I.F. **5.71**).
- 291.** Ardizzone A, Capra AP, Mondello S, et al. H1299R Variant in Factor V and Recurrent Pregnancy Loss: A Systematic Review and Meta-Analysis Protocol. *Genes (Basel)*. 2022;13(6):1019. Published 2022 Jun 6. doi:10.3390/genes13061019. (I.F. **4.14**).
- 292.** Rey F, Messa L, Maghraby E, et al. Oxygen sensing in neurodegenerative diseases: current mechanisms, implication of transcriptional response and pharmacological modulation [published online ahead of print, 2022 Jul 6]. *Antioxid Redox Signal*. 2022;10.1089/ars.2022.0046. doi:10.1089/ars.2022.0046. (I.F. **6.32**).
- 293.** Ardizzone A, Filippone A, Mannino D, et al. Ulva pertusa, a Marine Green Alga, Attenuates DNBS-Induced Colitis Damage via NF-κB/Nrf2/SIRT1 Signaling Pathways. *J Clin Med*. 2022;11(15):4301. Published 2022 Jul 25. doi:10.3390/jcm11154301. (I.F. **4.96**).
- 294.** Bova V, Filippone A, Casili G, et al. Adenosine Targeting as a New Strategy to Decrease Glioblastoma Aggressiveness. *Cancers (Basel)*. 2022;14(16):4032. Published 2022 Aug 20. doi:10.3390/cancers14164032. (I.F. **6.57**).

295. Filippone A, Mannino D, Cucinotta L, Paterniti I, Esposito E, Campolo M. LRRK2 Inhibition by PF06447475 Antagonist Modulates Early Neuronal Damage after Spinal Cord Trauma. *Antioxidants (Basel)*. 2022;11(9):1634. Published 2022 Aug 23. doi:10.3390/antiox11091634 (I.F 7.67).
296. Casili G, Lanza M, Filippone A, et al. Dimethyl Fumarate (DMF) Alleviated Post-Operative (PO) Pain through the N-Methyl-d-Aspartate (NMDA) Receptors. *Antioxidants (Basel)*. 2022;11(9):1774. Published 2022 Sep 8. doi:10.3390/antiox11091774. (I.F 7.67).
297. Filippone A, Scuderi SA, Basilotta R, Lanza M, Casili G, Bova V, Paterniti I, **Esposito E**. BAY-117082-driven NLRP3 inflammasome inhibition resolves nitro-glycerine (NTG) neuronal damage in in vivo model of migraine. *Biomed Pharmacother*. 2022 Dec;156:113851. doi: 10.1016/j.biopha.2022.113851. Epub 2022 Oct 15. PMID: 36252354. (IF: 7.419)
298. Marzocco S, Esposito G, **Esposito E**, Hassan STS. Editorial: Enteric inflammation and chronic diseases: Is there a link? *Front Pharmacol*. 2022 Oct 13;13:1018144. doi: 10.3389/fphar.2022.1018144. PMID: 36313353; PMCID: PMC9607915. (IF: 5.988)
299. Capra AP, Ardizzone A, Briuglia S, La Rosa MA, Mondello S, Campolo M, **Esposito E**. A Systematic Review and Meta-Analysis of the Association between the FV H1299R Variant and the Risk of Recurrent Pregnancy Loss. *Biology (Basel)*. 2022 Nov 3;11(11):1608. doi: 10.3390/biology11111608. PMID: 36358309. (IF: 5.168)
300. Scuderi SA, Filippone A, Basilotta R, Mannino D, Casili G, Capra AP, Chisari G, Colarossi L, Sava S, Campolo M, **Esposito E**, Paterniti I GSK343, an Inhibitor of Enhancer of Zeste Homolog 2, Reduces Glioblastoma Progression through Inflammatory Process Modulation: Focus on Canonical and Non-Canonical NF- κ B/I κ B α Pathways.. *Int J Mol Sci*. 2022;23(22):13915. Published 2022 Nov 11. doi:10.3390/ijms232213915 (I.F 6.208)
301. Braden K, Campolo M, Li Y, Chen Z, Doyle TM, Giancotti LA, **Esposito E**, Zhang J, Cuzzocrea S, Arnatt CK, Salvemini D. Activation of GPR183 by 7 α ,25-Dihydroxycholesterol Induces Behavioral Hypersensitivity through Mitogen-Activated Protein Kinase and Nuclear Factor- κ B. *J Pharmacol Exp Ther*. 2022 Nov;383(2):172-181. doi: 10.1124/jpet.122.001283. Epub 2022 Sep 18. PMID: 36116795; PMCID: PMC9553113. (I.F 4.402)
302. Paterniti I, Casili G, Filippone A, Lanza M, Ardizzone A, Capra AP, Campolo M, **Esposito E**. A New Approach for the Treatment of Recurrent Vulvovaginal Candidiasis with a Combination of Pea Protein, Grape Seed Extract, and Lactic Acid Assessed In Vivo. *J Fungi (Basel)*. 2022;8(12):1251. Published 2022 Nov 27. doi:10.3390/jof8121251. (IF 5.724)
303. Casili, G., Lanza, M., Filippone, A., Caffo, M., Paterniti, I., Campolo, M., Colarossi, L., Sciacca, D., Lombardo, S. P., Cuzzocrea, S., & **Esposito, E**. Overview on Common Genes Involved in the Onset of Glioma and on the Role of Migraine as Risk Factor: Predictive Biomarkers or Therapeutic Targets?. (2022). *Journal of personalized medicine*, 12(12), 1969. <https://doi.org/10.3390/jpm12121969>. (IF 3.508)
304. Filippone, A., Ardizzone, A., Bova, V., Lanza, M., Casili, G., Cuzzocrea, S., **Esposito, E**, Campolo, M., & Paterniti, I. A Combination of Xyloglucan, Pea Protein and Chia Seed Ameliorates Intestinal Barrier Integrity and Mucosa Functionality in a Rat Model of Constipation-Predominant Irritable Bowel Syndrome. (2022). *Journal of clinical medicine*, 11(23), 7073. <https://doi.org/10.3390/jcm11237073>. (IF 4,964)
305. Cucinotta, L., Filippone, A., Casili, G., Lanza, M., Bova, V., Capra, A. P., Giuffrida, R., Colarossi, C., Sciacca, D., Paterniti, I., Cuzzocrea, S., Campolo, M., & **Esposito, E**. The Pivotal Role of Protein Phosphatase 2A (PP2A) in Brain Tumors. (2022). *International journal of molecular sciences*, 23(24), 15717. <https://doi.org/10.3390/ijms232415717> (IF 6,208)
306. Filippone A, Mannino D, Casili G, Lanza M, Paterniti I, Cuzzocrea S, Capra AP, Colarossi L, Giuffrida D, Lombardo SP, **Esposito E**. Protein kinase inhibitors as a new target for immune system modulation and brain cancer management. *Int J Mol Sci*. 2022 Dec 10;23(24):15693. (IF 6.208)
307. Filippone A, Casili G, Scuderi SA, Mannino D, Lanza M, Campolo M, Paterniti I, Capra AP, Colarossi C, Bonasera A, Lombardo SP, Cuzzocrea S, **Esposito E**. Sodium propionate contributes to tumor cell growth inhibition through ppar- γ signaling. *Cancers (Basel)*. 2022 Dec 29;15(1):217. (IF 6.575)

308. Caffo M, Caruso G, Laera R, Curcio A, Cacciola F, **Esposito E**, Germanò A. The Role of Nanotechnology in Spinal Cord Tumors. *Adv Exp Med Biol.* 2023;1394:193-207. doi: 10.1007/978-3-031-14732-6_12. PMID: 36587389. (IF 3.65)
309. Rey F, Messa L, Maghraby E, Casili G, Ottolenghi S, Barzaghini B, Raimondi MT, Cereda C, Cuzzocrea S, Zuccotti G, **Esposito E**, Paterniti I, Carelli S. Oxygen Sensing in Neurodegenerative Diseases: Current Mechanisms, Implication of Transcriptional Response, and Pharmacological Modulation. *Antioxid Redox Signal.* 2023 Jan;38(1-3):160-182. doi: 10.1089/ars.2022.0046. PMID: 35793106. (IF 7.468)
310. Basilotta R, Lanza M, Filippone A, Casili G, Mannino D, De Gaetano F, Chisari G, Colarossi L, Motta G, Campolo M, Cuzzocrea S, Paterniti I, **Esposito E**. Therapeutic Potential of Dimethyl Fumarate in Counteract Oral Squamous Cell Carcinoma Progression by Modulating Apoptosis, Oxidative Stress and Epithelial-Mesenchymal Transition. *Int J Mol Sci.* 2023 Feb 1;24(3):2777. doi: 10.3390/ijms24032777. PMID: 36769105; PMCID: PMC9917022. (IF 6.208)
311. Capra AP, Ardizzone A, Pantò G, Paterniti I, Campolo M, Crupi L, Squeri R, **Esposito E**. The Prognostic Value of Pentraxin-3 in COVID-19 Patients: A Systematic Review and Meta-Analysis of Mortality Incidence. *Int J Mol Sci.* 2023 Feb 10;24(4):3537. doi: 10.3390/ijms24043537. PMID: 36834949; PMCID: PMC9958638. (IF 6.208)
312. Filippone A, Casili G, Lanza M, Scuderi SA, Ardizzone A, Capra AP, Paterniti I, Campolo M, Cuzzocrea S, **Esposito E**. Evaluation of the Efficacy of Xyloglucan, Pea Protein and Opuntia ficus-indica Extract in a Preclinical Model of Psoriasis. *Int J Mol Sci.* 2023 Feb 4;24(4):3122. doi: 10.3390/ijms24043122. PMID: 36834534; PMCID: PMC9966091. (IF 6.208)
313. Ammendolia I, Mannucci C, Cardia L, Calapai G, Gangemi S, **Esposito E**, Calapai F. Pharmacovigilance on cannabidiol as an antiepileptic agent. *Front Pharmacol.* 2023 Feb 10;14:1091978. doi: 10.3389/fphar.2023.1091978. PMID: 36843933; PMCID: PMC9950105. (IF 5.988)
314. Lanza M, Scuderi SA, Capra AP, Casili G, Filippone A, Campolo M, Cuzzocrea S, **Esposito E**, Paterniti I. Effect of a combination of pea protein, grape seed extract and lactic acid in an in vivo model of bacterial vaginosis. *Sci Rep.* 2023 Feb 17;13(1):2849. doi: 10.1038/s41598-023-28957-7. PMID: 36807330; PMCID: PMC9938223. (IF 4.996)
315. Lanza M, Cuzzocrea S, Oddo S, **Esposito E**, Casili G. The Role of miR-128 in Neurodegenerative Diseases. *Int J Mol Sci.* 2023 Mar 23;24(7):6024. doi: 10.3390/ijms24076024. PMID: 37046996; PMCID: PMC10093830. (IF 6.208)
316. Calapai M, Puzzo L, Bova G, Vecchio DA, Blandino R, Barbagallo A, Ammendolia I, Cardia L, De Pasquale M, Calapai F, **Esposito E**, Trimarchi F, Di Mauro D, Calapai G, Mannucci C. Effects of Physical Exercise and Motor Activity on Oxidative Stress and Inflammation in Post-Mastectomy Pain Syndrome. *Antioxidants (Basel).* 2023 Mar 4;12(3):643. doi: 10.3390/antiox12030643. PMID: 36978891; PMCID: PMC10045007. (IF 7.675)
317. Ardizzone A, Basilotta R, Filippone A, Crupi L, Lanza M, Lombardo SP, Colarossi C, Sciacca D, Cuzzocrea S, **Esposito E**, Campolo M. Recent Emerging Immunological Treatments for Primary Brain Tumors: Focus on Chemokine-Targeting Immunotherapies. *Cells.* 2023 Mar 8;12(6):841. doi: 10.3390/cells12060841. PMID: 36980182; PMCID: PMC10046911. (IF 7.666)
318. Ardizzone A, Bova V, Casili G, Repici A, Lanza M, Giuffrida R, Colarossi C, Mare M, Cuzzocrea S, **Esposito E**, Paterniti I. Role of Basic Fibroblast Growth Factor in Cancer: Biological Activity, Targeted Therapies, and Prognostic Value. *Cells.* 2023 Mar 24;12(7):1002. doi: 10.3390/cells12071002. PMID: 37048074; PMCID: PMC10093572. (IF 7.666)
319. Filippone A, Cucinotta L, Bova V, Lanza M, Casili G, Paterniti I, Campolo M, Cuzzocrea S, **Esposito E**. Inhibition of LRRK2 Attenuates Depression-Related Symptoms in Mice with Moderate Traumatic Brain Injury. *Cells.* 2023 Mar 29;12(7):1040. doi: 10.3390/cells12071040. PMID: 37048114; PMCID: PMC10093681. (IF 7.666)
320. Rey F, Berardo C, Maghraby E, Mauri A, Messa L, Esposito L, Casili G, Ottolenghi S, Bonaventura E, Cuzzocrea S, Zuccotti G, Tonduti D, **Esposito E**, Paterniti I, Cereda C, Carelli S. Redox Imbalance in Neurological Disorders in Adults and Children. *Antioxidants (Basel).* 2023 Apr 20;12(4):965. doi: 10.3390/antiox12040965. PMID: 37107340; PMCID: PMC10135575. (IF 7.675)

321. Ardizzone A, Mannino D, Capra AP, Repici A, Filippone A, **Esposito E**, Campolo M. New Insights into the Mechanism of *Ulva pertusa* on Colitis in Mice: Modulation of the Pain and Immune System. *Mar Drugs*. 2023 May 13;21(5):298. doi: 10.3390/md21050298. PMID: 37233492; PMCID: PMC10223675. (IF 6.085)
322. Casili, G.; Scuderi, S.A.; Lanza, M.; Filippone, A.; Mannino, D.; Giuffrida, R.; Colarossi, C.; Mare, M.; Capra, A.P.; De Gaetano, F.; et al. Therapeutic Potential of BAY-117082, a Selective NLRP3 Inflammasome Inhibitor, on Metastatic Evolution in Human Oral Squamous Cell Carcinoma (OSCC). *Cancers* 2023, 15, 2796. <https://doi.org/10.3390/cancers15102796> (IF 6.575)
323. Lanza M, Cucinotta L, Casili G, Filippone A, Basilotta R, Capra AP, Campolo M, Paterniti I, Cuzzocrea S, Esposito E. The Transcription Factor Nrf2 Mediates the Effects of *Anrodia camphorata* Extract on Neuropathological Changes in a Mouse Model of Parkinson's Disease. *Int J Mol Sci*. 2023 May 25;24(11):9250. doi: 10.3390/ijms24119250. PMID: 37298200; PMCID: PMC10252478. (IF 6.208)
324. Ardizzone A, Repici A, Capra AP, De Gaetano F, Bova V, Casili G, Campolo M, Esposito E. Efficacy of the Radical Scavenger, Tempol, to Reduce Inflammation and Oxidative Stress in a Murine Model of Atopic Dermatitis. *Antioxidants*. 2023; 12(6):1278. <https://doi.org/10.3390/antiox12061278> (IF 7.675)
325. Mannino D, Scuderi SA, Casili G, Bova V, Cucinotta L, Lanza M, Filippone A, Esposito E, Paterniti I. Neuroprotective effects of GSK-343 in an in vivo model of MPTP-induced nigrostriatal degeneration. *J Neuroinflammation*. 2023 Jun 30;20(1):155. doi: 10.1186/s12974-023-02842-6. PMID: 37391829; PMCID: PMC10311910. (IF 9.3)
326. Calapai F, Ammendolia I, Cardia L, Currò M, Calapai G, Esposito E, Mannucci C. Pharmacovigilance of Risankizumab in the Treatment of Psoriasis and Arthritic Psoriasis: Real-World Data from EudraVigilance Database. *Pharmaceutics*. 2023 Jul 11;15(7):1933. doi: 10.3390/pharmaceutics15071933. PMID: 37514118; PMCID: PMC10386550. (IF 5.4)
327. Capra AP, Ardizzone A, Crupi L, Calapai F, Campolo M, Cuzzocrea S, Esposito E. Efficacy of Palmitoylethanolamide and Luteolin Association on Post-Covid Olfactory Dysfunction: A Systematic Review and Meta-Analysis of Clinical Studies. *Biomedicines*. 2023 Aug 3;11(8):2189. doi: 10.3390/biomedicines11082189. PMID: 37626685; PMCID: PMC10452638. (IF 4.7)
328. Lanza M, Basilotta R, Cuzzocrea S, Bulzomi M, Oddo S, Casili G, Esposito E. An RNAi-Mediated Reduction in Transcription Factor Nrf-2 Blocks the Positive Effects of Dimethyl Fumarate on Metabolic Stress in Alzheimer's Disease. *Int J Mol Sci*. 2023 Jul 11;24(14):11303. doi: 10.3390/ijms241411303. PMID: 37511065; PMCID: PMC10378911. (IF 5.6)
329. Calapai F, Mannucci C, Cardia L, Currò M, Calapai G, Esposito E, Ammendolia I. Suspected oncologic adverse reactions associated with interleukin-23 inhibitors in EudraVigilance: Comparative study and gender distribution. *Pharmacol Res Perspect*. 2023 Oct;11(5):e01130. doi: 10.1002/prp2.1130. PMID: 37615258; PMCID: PMC10448453. (IF 2.6)
330. Cucinotta L, Mannino D, Casili G, Repici A, Crupi L, Paterniti I, Esposito E, Campolo M. Prolyl oligopeptidase inhibition ameliorates experimental pulmonary fibrosis both in vivo and in vitro. *Respir Res*. 2023 Aug 25;24(1):211. doi: 10.1186/s12931-023-02519-x. PMID: 37626373. (IF 5.8)

Ai sensi della legge 679/2016 del Regolamento del Parlamento Europeo del 27 aprile 2016, esprimo il mio consenso al trattamento e all'utilizzo dei dati forniti in questo CV

Messina, 29 Agosto 2023

